宮川 敬 (ミヤカワ ケイ)

総合イノベーション創発機構ワクチン研究開発拠点特任教授

研究テーマ
 経鼻粘膜ワクチンの開発・実用化に向けた基礎・臨床研究
 経鼻粘膜ワクチンの有効性評価法の開発
 高病原性鳥インフルエンザウイルスの性状解析

 Long COVID克服に向けた研究
 ヒト免疫不全ウイルスの潜伏・再活性化機構の研究

 

研究者基本情報

■ 学位
  • 博士(医学), 東京医科歯科大学, 2010年03月
■ URL
researchmap URLホームページURL■ ID 各種
研究者番号
  • 20580046
ORCID ID■ 研究キーワード・分野
研究キーワード
  • 経鼻粘膜ワクチン
  • 新型コロナウイルス
  • インフルエンザウイルス
  • ヒト免疫不全ウイルス
  • B型肝炎ウイルス
  • ウイルス学
  • ワクチン学
  • 分子生物学
  • 免疫学

経歴

■ 経歴
経歴
  • 2025年04月 - 現在
    国立健康危機管理研究機構, 国立感染症研究所インフルエンザ研究センター, 室長
  • 2022年10月 - 2025年03月
    国立感染症研究所, インフルエンザ・呼吸器系ウイルス研究センター, 室長
  • 2021年04月 - 2022年09月
    横浜市立大学, 医学部医学科 微生物学, 准教授
  • 2017年04月 - 2021年03月
    横浜市立大学, 医学部医学科 微生物学, 講師
  • 2012年08月 - 2017年03月
    横浜市立大学, 医学部医学科 微生物学, 助教
  • 2010年04月 - 2012年07月
    エイズ予防財団, リサーチレジデント

研究活動情報

■ 論文
  • Intracellular Zn2+ levels regulate susceptibility to hepatitis B virus infection by modulating NTCP-mediated viral entry.
    Yumi Itoh; Chiharu Morita; Cui Jinzi; Tatsuya Suzuki; Aiko Ono; Tomomi Hishinuma; Kento Fukano; Daisuke Okuzaki; Daisuke Motooka; Kei Miyakawa; Yasuyoshi Hatayama; Akihide Ryo; Mitsuyoshi Suzuki; Hajime Takei; Hiroshi Nittono; Tomohisa Tanaka; Koichi Watashi; Masamichi Muramatsu; Kohji Moriishi; Yoshiharu Matsuura; Toru Okamoto
    Antiviral research, 255, 106542, 106542, 2026年09月29日, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌), Hepatitis B virus (HBV) infection remains a significant global health challenge and is a leading cause of chronic liver diseases, including cirrhosis and hepatocellular carcinoma. Although nucleos(t)ide analogs and interferon-based therapies suppress viral replication, they do not eliminate the viral reservoir, highlighting the need for novel therapeutic strategies. HBV utilizes the sodium taurocholate cotransporting polypeptide (NTCP) as a key receptor for hepatocyte entry; however, the underlying mechanisms governing this process remain incompletely understood. In this study, we demonstrate that intracellular Zn2+ levels, regulated by zinc transporter 1 (ZnT1), also known as solute carrier family 30 member 1 (SLC30A1), serve as critical modulators of HBV entry. Zinc supplementation significantly reduced both HBV and hepatitis D virus infection in NTCP-expressing hepatocytes without affecting post-entry replication steps. Knockout or knockdown of SLC30A1 led to intracellular Zn2+ accumulation and impaired HBV infection, effects reversed by re-expression of functional SLC30A1 or treatment with the Zn2+ chelator TPEN. Mechanistically, elevated Zn2+ levels disrupted NTCP-mediated HBV/HDV internalization and bile acid uptake, implicating Zn2+ in the regulation of receptor activity. RNA sequencing analysis further revealed transcriptional reprogramming of metabolic and bile acid-associated pathways in Zn2+-treated cells. Collectively, these findings reveal a role for intracellular zinc homeostasis in regulating HBV entry and implicate the SLC30A1-Zn2+-NTCP axis in this process.
  • Selective Enrichment of Newly Synthesized Proteins Using Phos-Tag Click Tip Enables Nascent Proteome Analysis in Influenza A Virus Infection.
    Yayoi Kimura; Tomoko Akiyama; Tatsuhiro Kobashi; Maiko Hosotani; Yoko Ino; Jihye Shin; Naotoshi Nakamura; Eiji Kinoshita; Kei Miyakawa; Akihide Ryo
    Journal of proteome research, 25, 9, 4888, 4902, 2026年09月04日, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌), Profiling of newly synthesized proteins (NSPs) provides access to dynamic changes in protein production that accompany acute cellular responses. Bioorthogonal noncanonical amino acid tagging (BONCAT)-based approaches enable selective labeling of NSPs; however, their broader application remains constrained by labor-intensive enrichment workflows and limited sensitivity for direct peptide-level analysis. Here, we developed a workflow termed "Phos-tag Click Tip" by integrating a phosphorylated variant of bicyclononyne (pBCN) with Phos-tag affinity purification to selectively capture azidohomoalanine (AHA)-labeled peptides for newly synthesized proteome analysis (NSProteomics). This approach overcomes key limitations of conventional proteomics and BONCAT-based strategies by enabling efficient enrichment and sensitive detection of NSP-derived peptides. Using this workflow, we performed comprehensive NSP profiling of host cells during influenza A virus infection. We identified dynamic changes in distinct NSP profiles associated with viral replication, host restriction, and immune responses, many of which were not readily detected with conventional whole-cell- or phospho-proteomic analyses. Overall, the Phos-tag Click Tip workflow provides a complementary approach for stimulus-responsive NSP profiling, offering functionally relevant insights into host-virus interactions and cellular response mechanisms.
  • An endonuclease inhibitor unlocks the PA-X shutoff mechanism in influenza A virus.
    Kohei Oishi; Kaori Sano; Seiya Yamayoshi; Kei Miyakawa; Hideki Hasegawa; Yoshihiro Kawaoka
    Cell reports, 45, 9, 117921, 117921, 2026年09月01日, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌), Influenza A virus protein PA-X mediates host shutoff, yet its molecular mechanism and the role of its C-terminal region remain unclear. When ectopically expressed via plasmids, PA-X cleaves its own mRNAs, leading to remarkably low intracellular expression, which makes its characterization challenging. In this study, we utilize an endonuclease inhibitor to suppress PA-X shutoff activity, enabling its robust expression and purification. Our biochemical analyses reveal that PA-X directly binds RNA via its unique C-terminal basic-rich region and induces mRNA degradation with minimal sequence specificity. Furthermore, we find that while PA-X targets a broad range of RNAs, viral RNAs are protected from its endonuclease activity through their assembly into vRNP complexes. These findings provide critical insights into the PA-X-mediated shutoff strategy, revealing how PA-X modulates the cellular environment while sparing the viral genome to favor viral replication.
  • Lineage Diversification and Evolutionary Dynamics of the Hemagglutinin-Neuraminidase Gene in Mumps Virus Genotype G.
    Fuminori Mizukoshi; Miu Takada; Ryusuke Kimura; Wei Liu; Yasuyoshi Hatayama; Mayuko Nishi; Yuka Sato-Fujimoto; Akira Kimura; Fumihiro Kato; Kei Miyakawa; Hirokazu Kimura; Akihide Ryo
    Microorganisms, 14, 7, 2026年07月22日, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌), Mumps virus (MuV) genotype G is widely represented among circulating strains, but the evolutionary patterns of the hemagglutinin-neuraminidase (HN) gene remain incompletely understood. In this study, we analyzed publicly available full-length genotype G HN sequences using phylogenetic, phylodynamic, codon-based selection, and structure-guided epitope prediction approaches. The genotype G HN sequences were categorized into Clade 1, an operationally defined Diverse group, and Clade 2. Clade 1, which was composed mainly of Japanese strains, showed a relatively structured pattern over time. In contrast, Clade 2 showed more recent diversification and an overall increase in relative genetic diversity, although this phylodynamic pattern was sensitive to sampling structure. The Diverse group was phylogenetically heterogeneous, and its Bayesian skyline estimates were not used for biological interpretation because repeated analyses showed unstable posterior behavior. Root-to-tip regression supported temporal structure in the complete dataset, with the strongest signal in Clade 2. Bayesian molecular dating estimated the time to the most recent common ancestor of the sampled genotype G HN sequences at approximately 1932, and the mean evolutionary rate was 4.925 × 10-4 substitutions/site/year. Although the HN protein is a major surface antigen and a target of neutralizing antibodies, codon-based analyses showed no robust evidence of positive selection using multiple methods. Instead, many codon sites were inferred to be under purifying selection, suggesting that genotype G HN evolution is largely constrained by the need to maintain protein function. Predicted B-cell epitope regions were broadly similar among representative genotype G strains. Overall, these findings indicate that genotype G HN lineages have followed distinct evolutionary patterns, while the HN gene remains mainly shaped by purifying selection. These findings may help improve our understanding of MuV genotype G HN gene evolution and support future molecular surveillance.
  • Cross-neutralization of SARS-CoV-2 BA.3.2.2 lineage by JN.1 mRNA vaccine-induced immunity.
    Kei Miyakawa; Kaori Sano; Yohei Seki; Ryoichi Sato; Yasuo Yoshihara; Takuo Mizukami; Hideki Hasegawa
    International journal of infectious diseases, 108954, 108954, 2026年07月04日, [査読有り], [筆頭著者, 責任著者], [国際誌]
    英語, 研究論文(学術雑誌), The SARS-CoV-2 BA.3.2.2 sublineage has emerged globally as the dominant branch of BA.3.2 by late 2025, yet its antigenic relationship with JN.1 vaccine-induced immunity remains unclear. We evaluated neutralizing antibody responses in 25 JN.1 mRNA vaccinees against eight variants, stratified by anti-nucleocapsid antibody serostatus. Post-vaccination titers increased significantly against all variants in both N antibody-negative and -positive groups. Cross-neutralization against BA.3.2.2 was detected in both groups despite lower titers compared to JN.1. Antigenic cartography revealed that BA.3.2.2 was antigenically isolated from all JN.1-descendant variants. AZD3152/sipavibart retained potent neutralization against BA.3.2.2 but completely lost activity against all F456L-harboring JN.1-descendant variants, while VYD222/pemivibart and SA55 maintained broad activity. Retention of wild-type F456 in BA.3.2.2 preserves class 1/2 antibody epitopes, providing a mechanistic basis for cross-neutralization and suggesting a potential therapeutic window for sipavibart should BA.3.2.2 expand globally, pending clinical confirmation.
  • Dataset for the PHD3-mediated Hydroxylation Site Analysis in HIV-2 Vpx
    Yoko Ino; Yayoi Kimura; Kei Miyakawa; Akihide Ryo
    Journal of Proteome Data and Methods, 8, 3, 2026年05月30日, [査読有り]
  • Applications of Pseudoviruses Bearing Glycoproteins of SARS-CoV-2 and Influenza Virus.
    Makoto Ota; Kaori Sano; Kenji Yoshihara; Shinji Watanabe; Hideki Hasegawa; Kei Miyakawa
    Advances in experimental medicine and biology, 1491, 361, 372, 2026年04月01日, [査読有り], [責任著者], [国際誌]
    英語, 研究論文(学術雑誌), This review discusses pseudoviruses, which are chimeric viral particles constructed by replacing the envelope glycoproteins of viruses such as human immunodeficiency virus (HIV) or vesicular stomatitis virus (VSV) with those of target viruses, and their advantages in the study of highly pathogenic respiratory viruses. These systems serve as valuable tools for elucidating viral entry mechanisms, screening antiviral drugs, quantitatively assessing virus-neutralizing antibodies, and evaluating vaccine efficacy, while reducing the safety risks associated with live viruses. Despite limitations such as applicability primarily to enveloped viruses, ongoing technological advances continue to improve pseudovirus systems, increasing their utility in vaccine development, antiviral research, and rapid response to emerging infectious diseases.
  • Phylogenetic Analyses of RdRp Region and VP1 Gene in Human Norovirus Genotype GII.17[P17] Variants.
    Fuminori Mizukoshi; Yen Hai Doan; Asumi Hirata-Saito; Hiroyuki Tsukagoshi; Takumi Motoya; Ryusuke Kimura; Tomoko Takahashi; Yuriko Hayashi; Yuki Matsushima; Kei Miyakawa; Naomi Sakon; Kenji Sadamasu; Kazuhisa Yoshimura; Nobuhiro Saruki; Yoshiyuki Suzuki; Masashi Uema; Kosuke Murakami; Kazuhiko Katayama; Akihide Ryo; Tsutomu Kageyama; Hirokazu Kimura
    Microorganisms, 14, 4, 2026年03月28日, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌), In this study, we investigated the long-term evolutionary dynamics of human norovirus GII.17[P17] using the RNA-dependent RNA polymerase (RdRp) region and the VP1 capsid gene, integrating phylogenetics, time-scaled inference, phylodynamics, and structure-based analyses. Maximum-likelihood phylogenies of both genomic regions consistently resolved four major clades (Clades 1-4). VP1 patristic-distance distributions indicated higher within-clade diversity in the phylogenetically basal Clades 1 and 3, whereas Clades 2 and 4 showed lower diversity, consistent with recent demographic expansion. Similarity-plot analysis identified pronounced variability in the VP1 P2 domain, while the S and P1 domains remained comparatively conserved, supporting P2 as the primary hotspot of diversification. Bayesian time-scaled analyses estimated the most recent common ancestor around 1993 (VP1) and 2000 (RdRp) and revealed two major lineages (Clade 1/2 and Clade 3/4), with the split between Clades 3 and 4 occurring around 2016-2017. Bayesian skyline plots showed a marked increase in effective population size after 2013, and substitution-rate estimates indicated faster evolution in VP1 than in RdRp, with higher VP1 rates in the Clade 3/4 lineage than in Clade 1/2. Capsid dimer modeling further mapped high-confidence conformational B-cell epitopes and positively selected residues predominantly to the distal surface of P2, with broadly conserved spatial patterns across clades. Compared with the Clade 1 reference (Kawasaki323), Clade 2 accumulated numerous P2 substitutions, whereas Clades 3 and 4 retained fewer changes and remained closer to Clade 1 at the amino-acid level. Together, these results suggest lineage turnover within GII.17[P17] driven by constrained diversification at the P2 surface, potentially contributing to the recent predominance of the Clade 3/4 lineage.
  • Immune response and IgG subclass dynamics following repeated SARS-CoV-2 mRNA vaccination in Japanese healthcare workers.
    Kaori Sano; Hideaki Kato; Akihide Ryo; Hideki Hasegawa; Kei Miyakawa
    Vaccine, 77, 128396, 128396, 2026年02月26日, [査読有り], [責任著者], [国際誌]
    英語, 研究論文(学術雑誌), In Japan, many healthcare workers received up to seven doses of SARS-CoV-2 mRNA vaccines by April 2024. While repeated vaccination aims to strengthen immunity, concerns about immune imprinting and IgG subclass switching, particularly to IgG4, have arisen. This study examined 19 healthcare workers who completed seven doses. Serum and PBMCs collected at five or three time points respectively to measure were analyzed for IgG subclasses, neutralizing antibodies and cellular responses. IgG1-3 levels declined after the second dose but recovered after the third, whereas IgG4 increased post-second dose and remained stable. Neutralizing antibodies against Omicron XBB.1.5 were undetectable after two doses but appeared after the third, despite all being Wuhan strain vaccines, and rose further after the sixth and seventh doses with updated formulations. Cellular immunity remained stable throughout. These findings indicate repeated mRNA vaccination enhances humoral immunity without progressive IgG4 elevation or additional cellular response boosts.
  • USP45-mediated deubiquitination of HIV-1 Tat regulates viral transcription and latency.
    Kei Miyakawa; Hiyori Okura; Yasuyoshi Hatayama; Mayuko Nishi; Hirokazu Kimura; Hiroyuki Yamamoto; Hideki Hasegawa; Tetsuro Matano; Akihide Ryo
    Frontiers in microbiology, 17, 1656512, 1656512, 2026年01月26日, [査読有り], [筆頭著者, 責任著者], [国際誌]
    英語, 研究論文(学術雑誌), The HIV-1 Tat protein is regulated by post-translational modifications, particularly ubiquitination, but the full spectrum of deubiquitinating enzymes (DUBs) controlling HIV-1 transcription remains incompletely understood. We developed a NanoBRET-based screening system using a library of 120 DUB expression vectors and identified USP45 as a novel Tat-interacting DUB. Functional characterization revealed that USP45 specifically deubiquitinates Tat at lysine 19, targeting both K48-linked and K63-linked ubiquitin chains. Notably, USP45 overexpression suppressed Tat-dependent transcriptional activation and HIV-1 viral particle production, while USP45 knockdown enhanced both processes. Transcriptional profiling in latently infected J-Lat 8.4 cells using digital PCR revealed that USP45 primarily inhibits the initial stages of viral transcription, thereby contributing to the maintenance of the latent state by restricting downstream transcriptional processes. Furthermore, USP45 expression is induced by interferons, identifying it as an interferon-stimulated gene. These findings establish that USP45 functions as a host restriction factor that negatively regulates HIV-1 transcription by promoting Tat deubiquitination at lysine 19, representing a promising therapeutic target for controlling HIV-1 latency.
  • Onnamides A and B Suppress Hepatitis B Virus Transcription by Inhibiting Viral Promoter Activity.
    Yasuhiro Hayashi; Sei Arizono; Nanami Higa; Trianda Ayuning Tyas; Yuichi Akahori; Kenji Maeda; Masaaki Toyama; Kanami Mori-Yasumoto; Mina Yasumoto-Hirose; Kei Miyakawa; Junichi Tanaka; Takahiro Jomori
    Marine drugs, 24, 1, 2026年01月01日, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌), We recently reported that onnamide A, a marine-derived natural compound isolated from the sponge Theonella sp., inhibits the entry process of SARS-CoV-2 infection. However, its antiviral activity against other viruses remains largely unexplored. Here, we investigated the effects of onnamide A and its structurally related analog, onnamide B, on hepatitis B virus (HBV) infection. Using iNTCP cells, a hepatoblastoma-derived cell line permissive to HBV infection, we found that onnamides A and B exhibited cytotoxicity, with CC50 values of 0.53 ± 0.10 μM and 2.37 ± 0.25 μM, respectively. Following HBV infection, the levels of total HBV RNA were significantly reduced by onnamide A (IC50 = 0.06 ± 0.01 μM) and onnamide B (IC50 = 0.23 ± 0.06 μM). Notably, both compounds markedly decreased the levels of HBV pregenomic RNA. Furthermore, significant inhibition was particularly evident when onnamide treatment was initiated after HBV infection. Consistent with these observations, onnamides did not affect HBV binding, entry, or covalently closed circular DNA formation, but they significantly suppressed HBV RNA transcription. In particular, the transcriptional activities driven by the core and X promoters were markedly inhibited by onnamide treatment. Taken together, our findings demonstrate that onnamides possess potent anti-HBV activity and highlight their potential as candidate compounds targeting HBV RNA transcription.
  • CD46 regulates hepatitis B virus entry by modulating cell-surface NTCP levels through cis-interaction.
    Kei Miyakawa; Yusuke Nakai; Taichi Kameya; Hironori Nishitsuji; Koichi Watashi; Makoto Takeda; Tsukasa Seya; Kunitada Shimotohno; Yayoi Kimura; Akihide Ryo
    Journal of molecular cell biology, 2025年12月23日, [査読有り], [筆頭著者, 責任著者], [国際誌]
    英語, 研究論文(学術雑誌), Hepatitis B virus (HBV) infection remains a major global health challenge. While sodium taurocholate co-transporting polypeptide (NTCP) is the primary receptor for HBV entry, the molecular mechanisms regulating NTCP-mediated viral entry remain incompletely understood. Here, we identified CD46 as a crucial regulatory factor for NTCP membrane expression. We found that CD46 interacted with NTCP in cis at the plasma membrane through proximity-based labeling screening. The depletion of CD46 significantly reduced cell-surface NTCP levels and HBV infection in hepatocytes. Anti-CD46 monoclonal antibodies, particularly clone E4.3, inhibited HBV infection by triggering NTCP internalization from the plasma membrane to intracellular vesicles. The antiviral effect of CD46 antibodies was also confirmed in primary human hepatocytes. Our study reveals a previously unknown mechanism regulating NTCP-mediated HBV entry and suggests CD46 as a potential therapeutic target for HBV infection.
  • Risk assessment of SARS-CoV-2 infection from external surfaces and biological samples of COVID-19 corpses.
    Kazuho Maeda; Kei Miyakawa; Momoka Tanabe; Hikaru Kuninaka; Noriko Ogawa; Moe Mukai; Ayako Nasu; Chiaki Fuke; Yosuke Usumoto; Akihide Ryo; Yoko Ihama
    International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases, 108298, 108298, 2025年12月10日, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌), OBJECTIVES: The SARS-CoV-2 pandemic has resulted in millions of deaths worldwide. However, the risk of transmission from COVID-19 corpses remain unclear, posing challenges for forensic medicine in establishing effective infection control measures during autopsies. This study aimed to investigate the presence of infectious SARS-CoV-2 in corpses and identify factors affecting viral infectivity. METHODS: External examinations of 76 corpses with COVID-19 were performed, and nasopharyngeal, perioral, hand swabs, serum, cerebrospinal fluid (CSF), and urine samples were collected. Viral RNA was quantified by using digital PCR, and infectious viruses were assessed via isolation. Multivariate logistic regression analysis was used to identify factors associated with viral infectivity. RESULTS: Infectious viruses were isolated from the nasopharynx (51%), perioral region (10.3%), and hands (1.8%). Common predictive factors for nasopharyngeal and perioral viral infectivity were a higher viral load and shorter time from symptom onset. Detectable viral RNA in serum was also associated with nasopharyngeal infectivity. No infectious viruses were detected in serum, CSF, or urine samples. CONCLUSIONS: Infectious SARS-CoV-2 was detected in the nasopharynx and on the surface of COVID-19 corpses. Viral infectivity correlated with viral load and time from symptom onset, highlighting the importance of strict infection control when handling COVID-19 corpses.
  • Enhanced Detection of SARS-CoV-2 Using Platinum-Decorated Poly(2-vinylpyridine) Nanoparticle-Based Lateral Flow Immunoassay.
    Yayoi Kimura; Yasushi Enomoto; Yasufumi Matsumura; Kazuo Horikawa; Hideaki Kato; Atsushi Goto; Kei Miyakawa; Akihide Ryo
    Biomedicines, 13, 12, 2025年12月06日, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌), Background: Rapid and high-throughput diagnostic methods are essential for controlling the spread of infectious diseases, such as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Lateral flow immunoassay (LFIA) strips provide a cost-effective and user-friendly platform for point-of-care testing. However, the sensitivity of conventional LFIA kits is often limited by the performance of their detection probes. This study reports a highly sensitive LFIA strip for detecting the SARS-CoV-2 nucleocapsid (NP) protein using platinum-decorated poly(2-vinylpyridine) nanoparticles (Pt-P2VPs) as probes. Methods: Monoclonal antibodies against SARS-CoV-2 NP were conjugated with Pt-P2VPs and incorporated into LFIA strips. The test line was coated with anti-SARS-CoV-2 NP monoclonal antibody, and the control line with goat anti-mouse IgG. Recombinant proteins, viral strains, and nasopharyngeal swab specimens from patients were used to evaluate assay performance, with reverse transcription polymerase chain reaction (RT-PCR) as the reference standard. Diagnostic accuracy was assessed using nonparametric statistical tests. Results: Pt-P2VP-based LFIA strips enabled sensitive detection of recombinant NP and inactivated SARS-CoV-2, with minimal cross-reactivity. In 200 clinical specimens (100 PCR-negative and 100 PCR-positive), the assay achieved 74% sensitivity and 100% specificity, with strong correlation to viral RNA load. Compared with conventional LFIA kits, Pt-P2VP strips demonstrated superior sensitivity at lower viral loads. Conclusions: Pt-P2VPs represent a promising probe material for enhancing LFIA performance and may facilitate the development of rapid, sensitive, and scalable immunoassays for infectious disease diagnostics in biomedical applications.
  • Longitudinal monitoring of cellular immunity by the ex vivo activation of genes in leukocytes (EAGL) assay highlights potential markers of mRNA COVID-19 vaccine efficacy against breakthrough symptoms.
    Taro Saito; Arnaud Couzinet; Toshihiro Suzuki; Manami Shimomura; Akihide Ryo; Kei Miyakawa; Yuki Katayama; Tetsuya Nakatsura
    Vaccine, 68, 127942, 127942, 2025年11月06日, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌), mRNA vaccines have demonstrated broad effectiveness against coronavirus disease 2019 (COVID-19); nonetheless, substantial interindividual variability in vaccine-induced immunity limits our ability to predict protective efficacy at the individual level, particularly against severe manifestations of the disease. Cellular immune activity offers valuable insights into protection levels, yet assay complexity limits its large-scale evaluation. In this study, we aimed to evaluate the persistence of cellular immunity following COVID-19 mRNA vaccination and to assess its relationship with breakthrough infection severity. We used the streamlined, high-throughput ex vivo activation of genes in leukocytes (EAGL) assay to assess T-cell responses in blood samples from vaccinated Japanese donors by tracking immunity at intervals post-vaccination. Vaccine-induced cellular immunity persisted longer than the antibody titers. Notably, lower antibody titers tended to precede infection, whereas cellular immune responses did not correlate with the occurrence of breakthrough infection in our cohort. However, among breakthrough cases, asymptomatic donors showed a trend toward higher Th1/CD8+ T-cell cytokine responses (IFNG, IL2, TNFSF2) than those with mild symptoms, although these differences did not reach statistical significance. Transcriptome analysis identified CXCL9 as a potential novel marker for disease outcome, with reduced expression correlating with persistent symptoms. Interestingly, in individuals ≥55 years old, Th1/CD8+ T cell cytokine expression decreased significantly and CXCL9 expression fell below the threshold associated with persistent symptoms. By contrast, we did not observe a consistent age-related decline in humoral measures. Overall, our findings suggest that cellular immune readouts, particularly IFNG in combination with CXCL9, may serve as exploratory correlates of vaccine-mediated symptom attenuation. Furthermore, the EAGL assay constitutes an efficient and scalable platform for high-throughput assessment of vaccine-induced cellular immunity, offering potential as a predictive tool for individual-level vaccine efficacy in mitigating symptoms.
  • SARS-CoV-2 spike-specific IgG4 class switching associates with clinical recovery in Long COVID.
    Kaori Sano; Yayoi Kimura; Koichi Hirahata; Hideaki Kato; Hideki Hasegawa; Hidenori Akutsu; Akihide Ryo; Atsushi Goto; Kei Miyakawa
    Journal of infection, 91, 5, 106641, 106641, 2025年10月23日, [査読有り], [責任著者], [国際誌]
    英語
  • Positive correlation between structural disorder of the HIV-1 Gag N-terminal segment and progeny virus particle formation.
    Takaaki Koma; Osamu Kotani; Keisuke Kamba; Kei Miyakawa; Taiki Morita; Hiromi Nakamura; Masaru Yokoyama; Naoya Doi; Tomoyuki Kondo; Takashi Nagata; Akihide Ryo; Akio Adachi; Akira Ono; Masato Katahira; Masako Nomaguchi; Hironori Sato
    Journal of virology, e0088725, 2025年09月16日, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌), A class of unstructured peptide segments termed disordered regions plays a crucial role in the regulation of protein structure and function. Although the N-terminal region of the matrix (MA) domain of the HIV-1 Gag precursor protein is composed of an unstructured peptide, the mechanisms underlying the regulation of the unstructured state relating to control of viral phenotypes remain unclarified. We examined, in association, the structural, evolutionary, and biological roles of the MA N-terminal region via mutagenesis. Molecular dynamics simulation of a full-length Gag dimer model suggested that an amino acid residue at position 9 in the MA N-terminal region (MA-9) participates in the Gag dimerization. Information entropy analysis indicated that the MA-9 residue is variable in nature, but the hydrophobic amino acid substitution is evolutionarily maladaptive. Disordered region prediction study suggested that single hydrophobic amino acid substitutions at MA-9 reduce the disordered state of the MA N-terminal region. Consistently, NMR analysis indicated that such substitution reduces motional dynamics of the MA N-terminal region and alters the conformation of the MA domain. A site-directed mutagenesis study showed that hydrophobic amino acid substitutions at the MA-9 residue impair, to different degrees, the elementary and overall processes of virus particle formation in the cells. Importantly, the level of the virus particle formation was positively correlated with the level of disorder of the MA N-terminal region. These results indicate that the maintenance of structural disorder and dynamics of the Gag N-terminal segment is regulated by the MA-9 residue and critical for maintaining the optimal production of HIV-1 particles.IMPORTANCEA class of unstructured peptide segments termed disordered regions plays crucial roles in the regulation of protein structure and function. Although HIV-1 Gag precursor protein has multiple disordered elements, molecular mechanisms underlying regulation of unstructured state and viral phenotypes largely remain elusive. In this study, by analyzing in association the structural, evolutionary, and virological roles of the disordered N-terminal region of the HIV-1 Gag protein, we show that an amino acid residue at position 9 of the Gag is able to modulate the N-terminal disordered state, and the level of disorder of the Gag N-terminal region is positively correlated with the level of virus particle formation. Our findings gain new insights into molecular mechanisms of regulation of Gag structure and highlight the importance of a previously unappreciated survival strategy of HIV-1-namely, preservation of the Gag N-terminal disorder.
  • The role of HIV-1 Gag and genomic RNA interactions in virion assembly
    Takaaki Koma; Bao Quoc Le; Khanh Quoc Tran; Naoya Doi; Tomoyuki Kondo; Kei Miyakawa; Akio Adachi; Masako Nomaguchi
    Frontiers in Microbiology, 16, Frontiers Media SA, 2025年08月05日, [査読有り]
    研究論文(学術雑誌), The virion assembly represents a critical aspect of producing infectious progenies required for HIV-1 replication. Each step in that process, such as Gag-membrane binding, Gag-genomic RNA binding/packaging, Gag multimerization, and viral particle budding, has been extensively analyzed in a stepwise and specific manner. While Gag proteins are the primary drivers of HIV-1 virion assembly, the interactions between Gag and RNA play a significant role in regulating the process. This article provides an updated overview and perspective on HIV-1 virion assembly, with a particular focus on the role of Gag-RNA interactions.
  • Neutralizing antibody evasion of SARS-CoV-2 JN.1 derivatives KP.3, KP.3.1.1, LB.1, and XEC.
    Kaori Sano; Kei Miyakawa; Hideaki Kato; Yayoi Kimura; Atsushi Goto; Akihide Ryo; Shinji Watanabe; Hideki Hasegawa
    Vaccine, 62, 127472, 127472, 2025年07月09日, [査読有り], [責任著者], [国際誌]
    英語, 研究論文(学術雑誌), The emergence of SARS-CoV-2 variants poses ongoing challenges to vaccine efficacy. We evaluated neutralizing antibody responses against JN.1 and its derivatives (KP.3, KP.3.1.1, LB.1, and XEC) in healthcare workers who received seven doses of BNT162b2, including the XBB.1.5 monovalent vaccine. In COVID-19-naïve individuals, KP.3.1.1 and LB.1 showed substantial immune escape, whereas previously infected individuals maintained neutralization activity against all variants. We also demonstrated that JN.1-based immunization induces robust cross-neutralizing activity against emerging variants. A single amino acid deletion at position 31 in the spike protein may be associated with enhanced immune evasion. These findings support the potential effectiveness of JN.1-based vaccines while highlighting the need for continued surveillance and vaccine optimization.
  • PHD3-VHL axis controls HIV-2 infection through oxygen-dependent hydroxylation and degradation of Vpx.
    Kei Miyakawa; Kiho Tanaka; Yoko Ino; Yayoi Kimura; Taichi Kameya; Fuminori Mizukoshi; Mayuko Nishi; Masaru Yokoyama; Jun Nakabayashi; Masako Nomaguchi; Hironori Sato; Hirokazu Kimura; Hirofumi Akari; Tomoyuki Miura; Akinori Takaoka; Hideki Hasegawa; Tetsuro Matano; Yoji Andrew Minamishima; Akihide Ryo
    PLoS pathogens, 21, 6, e1013241, 2025年06月, [査読有り], [筆頭著者, 責任著者], [国際誌]
    英語, 研究論文(学術雑誌), HIV-2 viral protein X (Vpx) plays a pivotal role in antagonizing the host restriction factors, including SAMHD1 and components of the HUSH complex, to facilitate viral replication. However, the regulatory mechanisms controlling Vpx stability remain unclear. In this study, we identify the von Hippel-Lindau (VHL) tumor suppressor as a novel E3 ubiquitin ligase that specifically targets Vpx for proteasomal degradation. Mechanistically, we demonstrate that VHL-mediated degradation depends on the oxygen-dependent hydroxylation of Vpx at proline residue 41 (Pro41), a modification catalyzed by prolyl hydroxylase domain-containing protein 3 (PHD3). Using an integrated approach combining crosslinking mass spectrometry and molecular modeling analyses, we elucidate the structural architecture of the PHD3-Vpx complex, revealing the spatial orientation of the catalytic domain of PHD3 required for Pro41 hydroxylation. Furthermore, we establish the physiological significance of this pathway in human macrophages, where pharmacological inhibition or genetic ablation of VHL or PHD3 enhances HIV-2 infection by facilitating Vpx-mediated SAMHD1 degradation. Collectively, our findings unveil a previously unrecognized oxygen-sensitive regulatory mechanism influencing HIV-2 infection and suggest novel therapeutic strategies targeting Vpx stability through modulation of its prolyl hydroxylation status.
  • Emergence of Antigenic Variants in Bovine H5N1 Influenza Viruses.
    Kei Miyakawa; Makoto Ota; Kaori Sano; Fumitaka Momose; Noriko Kishida; Tomoko Arita; Yasushi Suzuki; Masayuki Shirakura; Hideki Asanuma; Shinji Watanabe; Hideki Hasegawa
    Journal of medical virology, 97, 5, e70394, 2025年05月, [査読有り], [筆頭著者, 責任著者], [国際誌]
    英語, 研究論文(学術雑誌), The recent emergence of the H5N1 influenza virus in dairy cattle has raised significant public health concerns. Using a previously established pseudovirus-based neutralization assay, we evaluated the impact of emerging hemagglutinin (HA) mutations on the efficacy of current candidate vaccine viruses (CVVs). Neutralization analysis revealed that the cow-derived H5N1 virus showed up to a 2.2-fold reduction in sensitivity compared to the CVV homologous neutralization titers. Among the 1,453 HA sequences analyzed from cow-derived H5N1 viruses, we identified four major mutations (E2K, D104G, V147M, and S336N) that emerged after the initial isolation, with 134 isolates (9.22%) harboring all four mutations. These multi-mutation variants exhibited up to a 3.3-fold reduction compared with the CVV homologous neutralization titers. Single-mutation analysis demonstrated that the D104G mutation, present in 47.8% of sequences, markedly contributed to antibody escape. Our findings highlight the importance of continued surveillance and antigenic evaluation of emerging variants for pandemic preparedness strategies.
  • Humoral and Cell-Mediated Immunity Against SARS-CoV-2 in Healthcare Personnel Who Received Multiple mRNA Vaccines: A 4-Year Observational Study.
    Hideaki Kato; Kaori Sano; Kei Miyakawa; Takayuki Kurosawa; Kazuo Horikawa; Yayoi Kimura; Atsushi Goto; Akihide Ryo
    Infectious disease reports, 17, 3, 2025年04月29日, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌), Background/Objectives: The long-term effects of multiple updated vaccinations against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) have not been clarified. Humoral or cellular immunity dynamics in healthcare workers for four years were analyzed. Methods: Blood samples were collected at five time points from April 2021 to January 2024. Humoral immunity was analyzed using the 50% neutralizing titer (NT50) against the original Omicron XBB and Omicron BA.2.86 strains and cellular immunity were analyzed using the ELISpot interferon-gamma releasing assay. NT50s and the spot-forming count (SFC) of the ELISpot assay were compared in the SARS-CoV-2 Omicron XBB-, Omicron-infected, and uninfected subjects. Results: 32 healthcare workers (median age, 47 years) who received 3-7 vaccine doses were enrolled. The NT50s against the original strain decreased after the second vaccination but were maintained after the third vaccine dose. NT50s against the Omicron XBB and BA.2.86 strains were detected before the Omicron vaccine was introduced and increased following the updated vaccination. The NT50s against the Omicron XBB and BA.2.86 strains were elevated after natural infection by the Omicron strain, albeit without differences compared with the findings in uninfected subjects. Multivariate regression analysis revealed no confounder that affected the antibody titer against the BA.2.86 strain at the fifth blood sampling. The median number of SFCs ranged from 78 to 208 after the first two doses. Conclusions: Multiple vaccinations induced the production of antibodies with divergent activity against emerging mutant strains and enhanced protective effects against the original strain. This finding supported the importance of updated vaccination.
  • Identification of Putative Serum Autoantibodies Associated with Post-Acute Sequelae of COVID-19 via Comprehensive Protein Array Analysis.
    Yasuyoshi Hatayama; Kei Miyakawa; Yayoi Kimura; Kazuo Horikawa; Kouichi Hirahata; Hirokazu Kimura; Hideaki Kato; Atsushi Goto; Akihide Ryo
    International journal of molecular sciences, 26, 4, 2025年02月19日, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌), Post-acute sequelae of SARS-CoV-2 infection (PASC), commonly known as "Long COVID", represents a significant clinical challenge characterized by persistent symptoms following acute COVID-19 infection. We conducted a comprehensive retrospective cohort study to identify serum autoantibody biomarkers associated with PASC. Initial screening using a protein bead array comprising approximately 20,000 human proteins identified several candidate PASC-associated autoantibodies. Subsequent validation by enzyme-linked immunosorbent assay (ELISA) in an expanded cohort-consisting of PASC patients, non-PASC COVID-19 convalescents, and pre-pandemic healthy controls-revealed two promising biomarkers: autoantibodies targeting PITX2 and FBXO2. PITX2 autoantibodies demonstrated high accuracy in distinguishing PASC patients from both non-PASC convalescents (area under the curve [AUC] = 0.891) and healthy controls (AUC = 0.866), while FBXO2 autoantibodies showed moderate accuracy (AUC = 0.762 and 0.786, respectively). Notably, the levels of these autoantibodies were associated with several PASC symptoms, including fever, dyspnea, palpitations, loss of appetite, and brain fog. The identification of PITX2 and FBXO2 autoantibodies as biomarkers not only enhances our understanding of PASC pathophysiology but also provides promising candidates for further investigation.
  • Reinfection Mechanisms of Various Viruses and Their Societal Implications.
    Ryusuke Kimura; Yuriko Hayashi; Yuka Sato-Fujimoto; Kei Miyakawa; Kazuya Shirato; Koo Nagasawa; Fuminori Mizukoshi; Takeshi Tsugawa; Akihide Ryo; Hirokazu Kimura
    Disease Biology, Genetics, and Socioecology, 1, 1, 2025年02月, [査読有り]
  • MARCH8 Restricts RSV Replication by Promoting Cellular Apoptosis Through Ubiquitin-Mediated Proteolysis of Viral SH Protein.
    Takashi Okura; Tatsuki Takahashi; Taichi Kameya; Fuminori Mizukoshi; Yusuke Nakai; Masatoshi Kakizaki; Mayuko Nishi; Noriyuki Otsuki; Hirokazu Kimura; Kei Miyakawa; Kazuya Shirato; Wataru Kamitani; Akihide Ryo
    Viruses, 16, 12, 2024年12月18日, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌), Numerous host factors function as intrinsic antiviral effectors to attenuate viral replication. MARCH8 is an E3 ubiquitin ligase that has been identified as a host restriction factor that inhibits the replication of various viruses. This study elucidated the mechanism by which MARCH8 restricts respiratory syncytial virus (RSV) replication through selective degradation of the viral small hydrophobic (SH) protein. We demonstrated that MARCH8 directly interacts with RSV-SH and catalyzes its ubiquitination at lysine 13, leading to SH degradation via the ubiquitin-lysosomal pathway. Functionally, MARCH8 expression enhances RSV-induced apoptosis through SH degradation, ultimately reducing viral titers. Conversely, an RSV strain harboring the SH-K13R mutation exhibited prolonged SH protein stability and attenuated apoptosis in infected cells, even in the presence of MARCH8. Targeted depletion of MARCH8 enhances cellular survival and potentially increases viral persistence. These findings demonstrate that MARCH8 promotes the early elimination of virus-infected cells by abrogating the anti-apoptotic function of SH, thereby reducing viral transmission. Our study provides novel insights into the interplay between host restriction factors and viral evasion strategies, potentially providing new therapeutic approaches for RSV infections.
  • Rapid and Safe Neutralization Assay for Circulating H5N1 Influenza Virus in Dairy Cows.
    Kei Miyakawa; Makoto Ota; Kaori Sano; Fumitaka Momose; Takashi Okura; Noriko Kishida; Tomoko Arita; Yasushi Suzuki; Masayuki Shirakura; Hideki Asanuma; Shinji Watanabe; Akihide Ryo; Hideki Hasegawa
    Influenza and other respiratory viruses, 18, 12, e70048, 2024年12月, [査読有り], [筆頭著者, 責任著者], [国際誌]
    英語, 研究論文(学術雑誌), Rapid and safe neutralization assays are required for highly pathogenic avian influenza viruses, including a clade 2.3.4.4b H5N1 subtype recently found in cows. Here, we report a neutralization assay using luminescent virus-like particles. This assay has lower biosafety requirements and provides a larger dynamic range than conventional methods. We applied this technique to evaluate the cross-reactivity of neutralizing antibodies induced by clade 2.3.4.4b candidate vaccine viruses (CVVs) with the cow-derived H5N1 virus. Our findings indicate that these CVVs share antigenic characteristics with the cow-derived H5N1 virus, suggesting the potential efficacy of vaccines developed using these CVVs.
  • Cellular and humoral immunity and IgG subclass distribution after omicron XBB.1.5 monovalent vaccination in Japan.
    Kaori Sano; Takayuki Kurosawa; Kazuo Horikawa; Yayoi Kimura; Atsushi Goto; Akihide Ryo; Hideki Hasegawa; Hideaki Kato; Kei Miyakawa
    Vaccine, 42, 26, 126452, 126452, 2024年10月16日, [査読有り], [責任著者], [国際誌]
    英語, 研究論文(学術雑誌), BACKGROUND: Up to seven doses of coronavirus disease 2019 (COVID-19) mRNA vaccines (BNT162b2) were administered to Japanese healthcare workers, until February 2024. The monovalent Omicron XBB.1.5 vaccine (hereafter called XBB.1.5 vaccine) was used for dose 7. OBJECTIVE: Although the XBB.1.5 vaccine has been reported to induce a robust increase in neutralizing antibodies against the currently circulating Omicron variant BA.2.86, little is known about its serological effects in Japan, where the BNT162b2 mRNA vaccine is the most frequently administered in the world. STUDY DESIGN: Twenty-five recipients of the XBB.1.5 vaccine, categorized as seronegative (n = 18) or seropositive (n = 7) based on their recent history of COVID-19, were analyzed. Neutralizing antibody titers against Omicron subvariants, receptor binding domain (RBD) IgG levels, IgG subclass distribution, and T-cell responses were assessed. RESULTS: We found a significant increase in neutralizing antibody titers against XBB.1.5 and BA.2.86 variants following XBB.1.5 vaccination, particularly in seropositive individuals. No significant change in total RBD IgG levels was observed, indicating efficient induction of antibodies targeting regions outside the RBD by XBB.1.5 vaccination. IgG subclass analysis demonstrated no significant subclass switching after vaccination. T-cell responses against the virus were comparable between seropositive and seronegative groups. CONCLUSIONS: The study suggests that XBB.1.5 vaccination enhances humoral immunity against Omicron variants without significant IgG subclass switching. However, some individuals with low pre-vaccination IgG titers did not exhibit increased antibody levels post-vaccination, raising concerns about potential immune tolerance.
  • 「ミニ腸」を用いたSARS-CoV-2変異株の性状解析と今後の展開
    宮川 敬
    ウイルス, 74, 1, 45, 48, 日本ウイルス学会, 2024年06月, [責任著者]
    日本語
  • Replication efficiency of SARS-CoV-2 Omicron subvariants BA.2.75, BA.5, and XBB.1 in human mini-gut organoids.
    Kei Miyakawa; Masakazu Machida; Tomoyuki Kawasaki; Masatoshi Kakizaki; Yayoi Kimura; Masaya Sugiyama; Hideki Hasegawa; Akihiro Umezawa; Hidenori Akutsu; Akihide Ryo
    Cellular and molecular gastroenterology and hepatology, 2024年03月15日, [査読有り], [筆頭著者, 責任著者], [国際誌]
    英語, 研究論文(学術雑誌)
  • Rapid quantitative detection system for measles virus-neutralizing antibodies using HiBiT-tagged virus-like particles.
    Takashi Okura; Kei Miyakawa; Maino Tahara; Kenji Someya; Fumio Seki; Mayuko Nishi; Noriyuki Otsuki; Akihide Ryo
    Microbiology and immunology, 2024年02月27日, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌), Immunological testing to detect neutralizing antibodies (NAbs) is important in measles (MV) infection control. Currently, the plaque reduction neutralization test is the only credible method for measuring actual virus NAbs; however, its feasibility is hampered by drawbacks, such as long turnaround times, low throughput, and the need for laboratory biosafety equipment. To solve these problems, we developed a simple and rapid MV-NAb detection system using lentivirus-based virus-like particles incorporated with the NanoLuc fragment peptide HiBiT comprising the MV fusion protein and hemagglutinin on their exterior surface. Overall, this simple, safe, and rapid method could be used to detect MV NAbs.
  • Humoral response against spike protein enhanced by fifth and sixth COVID-19 mRNA vaccine in the uninfected and infected subjects.
    Hideaki Kato; Takayuki Kurosawa; Kazuo Horikawa; Yayoi Kimura; Kei Miyakawa; Akihide Ryo; Atsushi Goto
    Human vaccines & immunotherapeutics, 19, 3, 2278376, 2278376, 2023年12月15日, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌), Antibody obtained by the coronavirus disease-19 (COVID-19) mRNA vaccine declines over time, and additional vaccinations are offered. It is not clear how repeated vaccination affects humoral immunity in uninfected individuals. We analyzed immunoglobulin G for spike protein (S-IgG) titers in COVID-19 uninfected and infected individuals vaccinated up to six times. The geometric mean S-IgG titers were 575.9 AU/mL and 369.0 AU/mL in those who received 6 and 5 doses less than 180 days after the last vaccination in uninfected subjects. In the 180-360 days after the last vaccination, the geometric mean S-IgG titers were 237.9 AU/mL and 128.6 AU/mL in the uninfected subjects who underwent five-dose and four-dose groups, respectively. Multivariate analysis showed that S-IgG titer increased 1.261-fold with each additional dose of mRNA vaccine. The S-IgG titers were 2.039-fold higher in the COVID-infected subjects compared to uninfected subjects. The positivity rate of nucleocapsid antibodies, suggesting a history of COVID-19, decreased 82% and 30% of COVID-infected cases after 180 and 360 days of infection, respectively. This result suggested that repeated vaccination with the COVID-19 mRNA vaccine may increase antibody titer in uninfected subjects.
  • Development of a contacting transwell co-culture system for the in vitro propagation of primary central nervous system lymphoma.
    Mayuko Nishi; Kensuke Tateishi; Jeremiah Stanleyraj Sundararaj; Yoko Ino; Yusuke Nakai; Yasuyoshi Hatayama; Yutaro Yamaoka; Yusaku Mihana; Kei Miyakawa; Hirokazu Kimura; Yayoi Kimura; Tetsuya Yamamoto; Akihide Ryo
    Frontiers in cell and developmental biology, 11, 1275519, 1275519, 2023年11月27日, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌), Primary central nervous system lymphoma (PCNSL) is a malignant neoplasm of the central nervous system that is refractory to treatment and has extremely poor prognosis. One factor hindering the development of therapeutic options for PCNSL is its molecular heterogeneity and the extreme difficulty in establishing in vitro cell lines that permit intensive research on this disease. In the present study, we developed a method to propagate PCNSL cells in vitro using a contacting transwell cell culture system involving brain vascular pericytes. The co-culture system was found to recapitulate the tumor microenvironment that is influenced by the biological activity of adjacent pericytes, and to sustain the survival and proliferation of PCNSL cells in vitro. We further delineated the underlying molecular mechanisms and found that the HGF-c-Met axis may be involved in the long-term in vitro culture of PCNSL cells. Moreover, the peptidylprolyl isomerase Pin1 was found to play a key role in PCNSL cell survival and it sustained proliferation through interactions with key transcription factors related to B-cell lymphomagenesis. These results suggest that our in vitro co-culture system is well suited to analyzing the biological and molecular characteristics of PCNSL, and may contribute to the discovery of new therapeutic interventions.
  • Photoimmunotechnology as a powerful biological tool for molecular-based elimination of target cells and microbes, including bacteria, fungi and viruses.
    Tadayuki Iwase; Kimihiro Ito; Takashi Nishimura; Kei Miyakawa; Akihide Ryo; Hisataka Kobayashi; Makoto Mitsunaga
    Nature protocols, 2023年10月04日, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌), Microbial pathogens, including bacteria, fungi and viruses, can develop resistance to clinically used drugs; therefore, finding new therapeutic agents is an ongoing challenge. Recently, we reported the photoimmuno-antimicrobial strategy (PIAS), a type of photoimmunotechnology, that enables molecularly targeted elimination of a wide range of microbes, including the viral pathogen severe acute respiratory syndrome coronavirus 2 and the multidrug-resistant bacterial pathogen methicillin-resistant Staphylococcus aureus (MRSA). PIAS works in the same way as photoimmunotherapy (PIT), which has been used to treat recurrent head and neck cancer in Japan since 2020. Both PIAS and PIT use a monoclonal antibody conjugated to a phthalocyanine derivative dye that undergoes a shape change when photoactivated. This shape change induces a structural change in the antibody-dye conjugate, resulting in physical stress within the binding sites of the conjugate and disrupting them. Therefore, targeting accuracy and flexibility can be determined based on the specificity of the antibody used. In this protocol, we describe how to design a treatment strategy, label monoclonal antibodies with the dye and characterize the products. We provide detailed examples of how to set up and perform PIAS and PIT applications in vitro and in vivo. These examples are PIAS against microbes using MRSA as a representative subject, PIAS against viruses using severe acute respiratory syndrome coronavirus 2 in VeroE6/TMPRSS2 cells, PIAS against MRSA-infected animals, and in vitro and in vivo PIT against cancer cells. The in vitro and in vivo protocols can be completed in ~3 h and 2 weeks, respectively.
  • Prediction models for neutralization activity against emerging SARS-CoV-2 variants: A cross-sectional study.
    Atsushi Goto#; Kei Miyakawa#; Izumi Nakayama; Susumu Yagome; Juan Xu; Makoto Kaneko; Norihisa Ohtake; Hideaki Kato; Akihide Ryo
    Frontiers in microbiology, 14, 1126527, 1126527, 2023年04月11日, [査読有り], [筆頭著者], [国際誌]
    英語, 研究論文(学術雑誌), OBJECTIVE: Despite extensive vaccination campaigns to combat the coronavirus disease (COVID-19) pandemic, variants of concern, particularly the Omicron variant (B.1.1.529 or BA.1), may escape the antibodies elicited by vaccination against SARS-CoV-2. Therefore, this study aimed to evaluate 50% neutralizing activity (NT50) against SARS-CoV-2 D614G, Delta, Omicron BA.1, and Omicron BA.2 and to develop prediction models to predict the risk of infection in a general population in Japan. METHODS: We used a random 10% of samples from 1,277 participants in a population-based cross-sectional survey conducted in January and February 2022 in Yokohama City, the most populous municipality in Japan. We measured NT50 against D614G as a reference and three variants (Delta, Omicron BA.1, and BA.2) and immunoglobulin G against SARS-CoV-2 spike protein (SP-IgG). RESULTS: Among 123 participants aged 20-74, 93% had received two doses of SARS-CoV-2 vaccine. The geometric means (95% confidence intervals) of NT50 were 65.5 (51.8-82.8) for D614G, 34.3 (27.1-43.4) for Delta, 14.9 (12.2-18.0) for Omicron BA.1, and 12.9 (11.3-14.7) for Omicron BA.2. The prediction model with SP-IgG titers for Omicron BA.1 performed better than the model for Omicron BA.2 (bias-corrected R 2 with bootstrapping: 0.721 vs. 0.588). The models also performed better for BA.1 than for BA.2 (R 2 = 0.850 vs. 0.150) in a validation study with 20 independent samples. CONCLUSION: In a general Japanese population with 93% of the population vaccinated with two doses of SARS-CoV-2 vaccine, neutralizing activity against Omicron BA.1 and BA.2 were substantially lower than those against D614G or the Delta variant. The prediction models for Omicron BA.1 and BA.2 showed moderate predictive ability and the model for BA.1 performed well in validation data.
  • Integrated Tandem Affinity Protein Purification Using the Polyhistidine Plus Extra 4 Amino Acids (HiP4) Tag System.
    Yoko Ino; Yutaro Yamaoka; Kiho Tanaka; Kei Miyakawa; Mayuko Nishi; Yasuyoshi Hatayama; Hirokazu Kimura; Yayoi Kimura; Akihide Ryo
    Proteomics, 23, 11, e2200334, 2023年02月20日, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌), Peptide tag systems are a robust biophysical and biochemical method that is widely used for protein detection and purification. Here, we developed a novel tag system termed "HiP4" (histidine plus four amino acids) whose epitope sequence comprises only seven amino acids (HHHDYDI) that partially overlap with the conventional 6x histidine tag. We produced a monoclonal antibody against the HiP4 tag that can be used in multiple immunoassays with high specificity and affinity. Using this system, we developed a tandem affinity purification and mass spectrometry (TAP-MS) system for comprehensive protein interactome analysis. The integrated use of nickel bead purification followed by HiP4 tag immunoprecipitation made it possible to reduce nonspecific binding and improve selectivity, leading to the recovery of previously unrecognized proteins that interact with hepatitis B virus X protein or TAR DNA-binding protein 43. Our results indicate that this system may be viable as a simple and powerful tool for TAP-MS that can achieve low background and high selectivity in comprehensive protein-protein interaction analyses. This article is protected by copyright. All rights reserved.
  • 新興再興感染症に対する宿主防御機構の解明と治療法開発に向けた基盤研究
    宮川敬
    横浜医学, 73, 4, 577, 581, 横浜市立大学医学会, 2022年12月, [責任著者]
    日本語
  • Generation and Utilization of a Monoclonal Antibody against Hepatitis B Virus Core Protein for a Comprehensive Interactome Analysis.
    Yusuke Nakai; Kei Miyakawa; Yutaro Yamaoka; Yasuyoshi Hatayama; Mayuko Nishi; Hidefumi Suzuki; Hirokazu Kimura; Hidehisa Takahashi; Yayoi Kimura; Akihide Ryo
    Microorganisms, 10, 12, 2022年11月30日, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌), Hepatitis B virus (HBV) core antigen (HBc) is a structural protein that forms the viral nucleocapsid and is involved in various steps of the viral replication cycle, but its role in the pathogenesis of HBV infection is still elusive. In this study, we generated a mouse monoclonal antibody (mAb) against HBc and used it in antibody-based in situ biotinylation analysis in order to identify host proteins that interact with HBc. HBc antigen was produced with a wheat germ cell-free protein synthesis system and used to immunize mice. Among the established hybridoma clones, a single clone (mAb #7) was selected and further characterized for its ability in the antibody-based in situ biotinylation analysis to collect host proteins that are in the vicinity of HBc. Using mass spectrometry, we identified 215 HBc-interacting host proteins, three of which bind HBc most significantly under hypoxic conditions. Our results indicate that mAb #7 can be used to systematically identify host proteins that interact with HBc under pathophysiological conditions, and thus may be useful to explore the molecular pathways involved in HBV-induced cytopathogenesis.
  • Intratracheal trimerized nanobody cocktail administration suppresses weight loss and prolongs survival of SARS-CoV-2 infected mice.
    Kayoko Nagata; Daichi Utsumi; Masamitsu N Asaka; Ryota Maeda; Kotaro Shirakawa; Yasuhiro Kazuma; Ryosuke Nomura; Yoshihito Horisawa; Yohei Yanagida; Yugo Kawai; Kei Sato; Yutaro Yamaoka; Kei Miyakawa; Akihide Ryo; Yasuhiro Yasutomi; Akihiro Imura; Akifumi Takaori-Kondo
    Communications medicine, 2, 1, 152, 152, 2022年11月26日, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌), BACKGROUND: SARS-CoV-2 Omicron variants are highly resistant to vaccine-induced immunity and human monoclonal antibodies. METHODS: We previously reported that two nanobodies, P17 and P86, potently neutralize SARS-CoV-2 VOCs. In this study, we modified these nanobodies into trimers, called TP17 and TP86 and tested their neutralization activities against Omicron BA.1 and subvariant BA.2 using pseudovirus assays. Next, we used TP17 and TP86 nanobody cocktail to treat ACE2 transgenic mice infected with lethal dose of SARS-CoV-2 strains, original, Delta and Omicron BA.1. RESULTS: Here, we demonstrate that a novel nanobody TP86 potently neutralizes both BA.1 and BA.2 Omicron variants, and that the TP17 and TP86 nanobody cocktail broadly neutralizes in vitro all VOCs as well as original strain. Furthermore, intratracheal administration of this nanobody cocktail suppresses weight loss and prolongs survival of human ACE2 transgenic mice infected with SARS-CoV-2 strains, original, Delta and Omicron BA.1. CONCLUSIONS: Intratracheal trimerized nanobody cocktail administration suppresses weight loss and prolongs survival of SARS-CoV-2 infected mice.
  • Prospective Clinical Evaluation of the Diagnostic Accuracy of a Highly Sensitive Rapid Antigen Test Using Silver Amplification Technology for Emerging SARS-CoV-2 Variants.
    Kazuaki Obata; Kei Miyakawa; Toshiki Takei; Atsuhiko Wada; Yasuyoshi Hatayama; Hideaki Kato; Yayoi Kimura; Hisakuni Sekino; Junichi Katada; Akihide Ryo
    Biomedicines, 10, 11, 2022年11月03日, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌), The COVID-19 pandemic caused by SARS-CoV-2 remains a serious health concern worldwide due to outbreaks of SARS-CoV-2 variants that can escape vaccine-acquired immunity and infect and transmit more efficiently. Therefore, an appropriate testing method for COVID-19 is essential for effective infection control and the prevention of local outbreaks. Compared to reverse-transcription polymerase chain reaction (RT-PCR) tests, antigen tests are used for simple point-of-care testing, enabling the identification of viral infections. In this study, we tested the clinical usefulness of the FUJIFILM COVID-19 Ag test, an antigen test based on silver amplification and immunochromatographic technology. The FUJIFILM COVID-19 Ag test was shown to detect a lower viral concentration as compared to other conventional kits without significant performance loss in detecting prevalent SARS-CoV-2 variants. We tested nasopharyngeal and nasal swabs from a single patient during two different epidemic periods dominated by various SARS-CoV-2 variants. We observed that the sensitivity of the FUJIFILM COVID-19 Ag test was 95.7% and 85.7% in nasopharyngeal and nasal swabs, respectively. These results suggest that the FUJIFILM COVID-19 Ag test is highly sensitive and applicable when RT-PCR testing is unavailable. Furthermore, these results indicate that high-frequency testing using nasal swab specimens may be a valuable screening strategy.
  • Development of a Monoclonal Antibody Targeting HTLV-1 Envelope gp46 Glycoprotein and Its Application to Near-Infrared Photoimmuno-Antimicrobial Strategy.
    Yasuyoshi Hatayama; Yutaro Yamaoka; Takeshi Morita; Sundararaj Stanleyraj Jeremiah; Kei Miyakawa; Mayuko Nishi; Yayoi Kimura; Makoto Mitsunaga; Tadayuki Iwase; Hirokazu Kimura; Naoki Yamamoto; Akifumi Takaori-Kondo; Hideki Hasegawa; Akihide Ryo
    Viruses, 14, 10, 2022年09月29日, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌), Human T-cell leukemia virus type 1 (HTLV-1), a retrovirus, causes adult T-cell leukemia-lymphoma, HTLV-1 associated myelopathy/tropical spastic paraparesis, and HTLV-1 uveitis. Currently, no antiretroviral therapies or vaccines are available for HTLV-1 infection. This study aimed to develop an antibody against the HTLV-1 envelope protein (Env) and apply it to a near-infrared photoimmuno-antimicrobial strategy (NIR-PIAS) to eliminate HTLV-1 infected cells. We established mouse monoclonal antibodies (mAbs) against HTLV-1 Env by immunization with a complex of liposome and the recombinant protein. Detailed epitope mapping revealed that one of the mAbs bound to the proline-rich region of gp46 and exhibited no obvious neutralizing activity to inhibit viral infection. Instead, the mAb was rarely internalized intracellularly and remained on the cell surface of HTLV-1-infected cells. The antibody conjugated to the photosensitive dye IRDye700Dx recognized HTLV-1 infected cells and killed them following NIR irradiation. These results suggest that the novel mAb and NIR-PIAS could be developed as a new targeted therapeutic tool against HTLV-1 infected cells.
  • Development of a Fully Automated Desktop Analyzer and Ultrahigh Sensitivity Digital Immunoassay for SARS-CoV-2 Nucleocapsid Antigen Detection.
    Ryotaro Chiba; Kei Miyakawa; Kotaro Aoki; Takamitsu J Morikawa; Yoshiki Moriizumi; Takuma Degawa; Yoshiyuki Arai; Osamu Segawa; Kengo Tanaka; Hideji Tajima; Susumu Arai; Hisatoshi Yoshinaga; Ryohei Tsukada; Akira Tani; Haruhito Fuji; Akinobu Sato; Yoshikazu Ishii; Kazuhiro Tateda; Akihide Ryo; Toru Yoshimura
    Biomedicines, 10, 9, 2022年09月15日, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌), BACKGROUND: The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) outbreak has had a significant impact on public health and the global economy. Several diagnostic tools are available for the detection of infectious diseases, with reverse transcription-polymerase chain reaction (RT-PCR) testing specifically recommended for viral RNA detection. However, this diagnostic method is costly, complex, and time-consuming. Although it does not have sufficient sensitivity, antigen detection by an immunoassay is an inexpensive and simpler alternative to RT-PCR. Here, we developed an ultrahigh sensitivity digital immunoassay (d-IA) for detecting SARS-CoV-2 nucleocapsid (N) protein as antigens using a fully automated desktop analyzer based on a digital enzyme-linked immunosorbent assay. METHODS: We developed a fully automated d-IA desktop analyzer and measured the viral N protein as an antigen in nasopharyngeal (NP) swabs from patients with coronavirus disease. We studied nasopharyngeal swabs of 159 and 88 patients who were RT-PCR-negative and RT-PCR-positive, respectively. RESULTS: The limit of detection of SARS-CoV-2 d-IA was 0.0043 pg/mL of N protein. The cutoff value was 0.029 pg/mL, with a negative RT-PCR distribution. The sensitivity of RT-PCR-positive specimens was estimated to be 94.3% (83/88). The assay time was 28 min. CONCLUSIONS: Our d-IA system, which includes a novel fully automated desktop analyzer, enabled detection of the SARS-CoV-2 N-protein with a comparable sensitivity to RT-PCR within 30 min. Thus, d-IA shows potential for SARS-CoV-2 detection across multiple diagnostic centers including small clinics, hospitals, airport quarantines, and clinical laboratories.
  • Enhancement of humoral and cellular immunity against SARS-CoV-2 by a third dose of BNT162b2 vaccine in Japanese healthcare workers.
    Kei Miyakawa; Hideaki Kato; Norihisa Ohtake; Sundararaj Stanleyraj Jeremiah; Akihide Ryo
    The Journal of infectious diseases, 2022年08月18日, [査読有り], [筆頭著者], [国際誌]
    英語, 研究論文(学術雑誌), The Omicron variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has raised concerns regarding vaccine effectiveness. We investigated humoral and cellular immune responses against SARS-CoV-2 in healthcare workers before and after a third (booster) dose of the BNT162b2 mRNA vaccine. It significantly enhanced both humoral and cellular immunity in previously uninfected individuals. However, cellular immunity was not enhanced in previously infected persons, suggesting that three antigenic stimuli by vaccination or natural infection reached a plateau of cellular immunity. Even with reinforced immunity to SARS-CoV-2, we confirmed several post-booster breakthrough cases caused by the Omicron variant.
  • A panel of nanobodies recognizing conserved hidden clefts of all SARS-CoV-2 spike variants including Omicron.
    Ryota Maeda; Junso Fujita; Yoshinobu Konishi; Yasuhiro Kazuma; Hiroyuki Yamazaki; Itsuki Anzai; Tokiko Watanabe; Keishi Yamaguchi; Kazuki Kasai; Kayoko Nagata; Yutaro Yamaoka; Kei Miyakawa; Akihide Ryo; Kotaro Shirakawa; Kei Sato; Fumiaki Makino; Yoshiharu Matsuura; Tsuyoshi Inoue; Akihiro Imura; Keiichi Namba; Akifumi Takaori-Kondo
    Communications biology, 5, 1, 669, 669, Cold Spring Harbor Laboratory, 2022年07月06日, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌), We are in the midst of the historic coronavirus infectious disease 2019 (COVID-19) pandemic caused by severe respiratory syndrome coronavirus 2 (SARS-CoV-2). Although countless efforts to control the pandemic have been attempted—most successfully, vaccination1–3—imbalances in accessibility to vaccines, medicines, and diagnostics among countries, regions, and populations have been problematic. Camelid variable regions of heavy chain-only antibodies (VHHs or nanobodies)4 have unique modalities: they are smaller, more stable, easier to customize, and, importantly, less expensive to produce than conventional antibodies5, 6. We present the sequences of nine alpaca nanobodies that detect the spike proteins of four SARS-CoV-2 variants of concern (VOCs)—namely, the alpha, beta, gamma, and delta variants. We show that they can quantify or detect spike variants via ELISA and lateral flow, kinetic, flow cytometric, microscopy, and Western blotting assays7. The panel of nanobodies broadly neutralized viral infection by pseudotyped SARS-CoV-2 VOCs. Structural analyses showed that a P86 clone targeted epitopes that were conserved yet unclassified on the receptor-binding domain (RBD) and located inside the N-terminal domain (NTD). Human antibodies have hardly accessed both regions; consequently, the clone buries hidden crevasses of SARS-CoV-2 spike proteins undetected by conventional antibodies and maintains activity against spike proteins carrying escape mutations.
  • Antimicrobial strategy for targeted elimination of different microbes, including bacterial, fungal and viral pathogens.
    Makoto Mitsunaga; Kimihiro Ito; Takashi Nishimura; Hironori Miyata; Kei Miyakawa; Takeshi Morita; Akihide Ryo; Hisataka Kobayashi; Yoshimitsu Mizunoe; Tadayuki Iwase
    Communications biology, 5, 1, 647, 647, Springer Science and Business Media LLC, 2022年07月04日, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌), Abstract

    The continuous emergence of microbial pathogens for which there are no effective antimicrobials threatens global health, necessitating novel antimicrobial approaches. Here, we present a targeted antimicrobial strategy that can be applied to various microbial pathogens. A photoimmuno-conjugate composed of an antibody against the target pathogen and a photoplastic phthalocyanine-derivative probe that generates photo-induced mechanical stress was developed based on photoimmuno-technology. This strategy, named as photoimmuno-antimicrobial strategy (PIAS), eliminates targeted pathogens, regardless of the target species or drug-resistance status. Specifically, PIAS acts on a broad range of microbes, including the bacterial pathogen Staphylococcus aureus, fungal pathogen Candida albicans, including their drug-resistant strains, and viral pathogen SARS-CoV-2, the causative agent of COVID-19. Furthermore, PIAS protects mice from fatal infections without damaging the non-targeted host microbiota and tissues. This study may contribute to the development of next-generation anti-infective therapies.
  • Characterization and Utilization of Disulfide-Bonded SARS-CoV-2 Receptor Binding Domain of Spike Protein Synthesized by Wheat Germ Cell-Free Production System
    Yutaro Yamaoka; Sundararaj Stanleyraj Jeremiah; Rikako Funabashi; Kei Miyakawa; Takeshi Morita; Yusaku Mihana; Hideaki Kato; Akihide Ryo
    Viruses, 14, 7, 1461, 1461, MDPI AG, 2022年07月01日, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌), The spike protein (SP) of SARS-CoV-2 is an important target for COVID-19 therapeutics and vaccines as it binds to the ACE2 receptor and enables viral infection. Rapid production and functional characterization of properly folded SP is of the utmost importance for studying the immunogenicity and receptor-binding activity of this protein considering the emergence of highly infectious viral variants. In this study, we attempted to express the receptor-binding region (RBD) of SARS-CoV-2 SP containing disulfide bonds using the wheat germ cell-free protein synthesis system. By adding protein disulfide isomerase (PDI) and endoplasmic reticulum oxidase (ERO1α) to the translational reaction mixture, we succeeded in synthesizing a functionally intact RBD protein that can interact with ACE2. Using this RBD protein, we have developed a high-throughput AlphaScreen assay to evaluate the RBD–ACE2 interaction, which can be applied for drug screening and mutation analysis. Thus, our method sheds new light on the structural and functional properties of SARS-CoV-2 SP and has the potential to contribute to the development of new COVID-19 therapeutics.
  • Development of Parallel Reaction Monitoring Mass Spectrometry Assay for the Detection of Human Norovirus Major Capsid Protein
    Yayoi Kimura; Jihye Shin; Yusuke Nakai; Masaya Takahashi; Yoko Ino; Tomoko Akiyama; Keiko Goto; Noriko Nagata; Yutaro Yamaoka; Kei Miyakawa; Hirokazu Kimura; Akihide Ryo
    Viruses, 14, 7, 1416, 1416, MDPI AG, 2022年06月28日, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌), Human Norwalk viruses (HuNoVs), the most common etiological agents of acute gastroenteritis, are genetically diverse RNA viruses that frequently cause mass food poisoning internationally. Although nucleic acid detection methods, such as reverse transcription–quantitative polymerase chain reaction (RT-qPCR), are the gold standard for the diagnosis of norovirus infection, alternative methods are needed for the specific and sensitive viral protein detection for rapid diagnosis and surveillance. In this study, we developed a robust and high-throughput targeted proteomic assay workflow to directly detect the VP1 major capsid protein of HuNoVs. A parallel reaction monitoring (PRM) assay using a high-resolution mass spectrometer was used to detect representative peptides derived from VP1 in six different HuNoV genotypes. An optimized protocol using synthesized heavy isotope-labeled peptides as internal standards was also used to simultaneously genotype and quantify the VP1 protein in human stool specimens. This method is expected to become a new tool for studying the molecular epidemiology of HuNoV and to shed new light on targeted proteomics in clinical practice.
  • Inhibition of nonhomologous end joining-mediated DNA repair enhances anti-HBV CRISPR therapy.
    Kazuhiro Murai; Takahiro Kodama; Hayato Hikita; Akiyoshi Shimoda; Makoto Fukuoka; Keisuke Fukutomi; Satoshi Shigeno; Yuto Shiode; Daisuke Motooka; Yuichiro Higuchi; Kei Miyakawa; Hiroshi Suemizu; Akihide Ryo; Yuki Tahata; Yuki Makino; Ryoko Yamada; Ryotaro Sakamori; Tomohide Tatsumi; Tetsuo Takehara
    Hepatology communications, 6, 9, 2474, 2487, 2022年05月24日, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌), Current anti-hepatitis B virus (HBV) therapies have little effect on covalently closed circular DNA (cccDNA) and fail to eliminate HBV. The clustered regularly interspaced short palindromic repeat (CRISPR)/Cas9 system has been reported to directly target cccDNA and exert antiviral effects. In this study, we hypothesized that the inhibition of the DNA repair machinery, which is important for the repair of CRISPR-induced double-strand breaks, may enhance the effect of CRISPR targeting cccDNA, and we investigated the antiviral effect of potential combination therapy. The antiviral effect of CRISPR targeting cccDNA (HBV-CRISPR) was evaluated in HBV-susceptible HepG2-hNTCP-C4 cells expressing Cas9 (HepG2-hNTCP-C4-iCas9) or primary human hepatocytes (PHHs) expressing Cas9. Following HBV infection, HBV-CRISPR reduced cccDNA levels, accompanied by decreases in pregenomic RNA (pgRNA) levels and supernatant HBV DNA, hepatitis B surface antigen and hepatitis B e antigen levels in HepG2-hNTCP-C4-iCas9 cells, and PHHs. HBV-CRISPR induced indel formation in cccDNA and up-regulated poly(adenosine diphosphate ribose) polymerase (PARP) activity in HBV-infected HepG2-hNTCP-C4-iCas9 cells. The suppression of PARP2-Histone PARylation factor 1 (HPF1) (involved in the initial step of DNA repair) with small interfering RNA (siRNA) targeting either PARP2 or HPF1 increased the reduction in pgRNA and cccDNA by HBV-CRISPR in HBV-infected HepG2-hNTCP-C4-iCas9 cells. The suppression of DNA Ligase 4 (LIG4) (essential for nonhomologous end joining [NHEJ]) but not breast cancer susceptibility gene (BRCA) (essential for homologous recombination) enhanced the antiviral effect of HBV-CRISPR in HBV-infected HepG2-hNTCP-C4-iCas9 cells. Finally, the clinically available PARP inhibitor olaparib increased the reductions in pgRNA and cccDNA levels induced by HBV-CRISPR in HBV-infected HepG2-hNTCP-C4-iCas9 cells and PHHs. Conclusion: The suppression of the NHEJ-mediated DNA repair machinery enhances the effect of CRISPR targeting cccDNA. The combination of CRISPR and olaparib may represent a therapy for HBV elimination.
  • Reduced replication efficacy of SARS-CoV-2 Omicron variant in "mini-gut" organoids.
    Kei Miyakawa; Masakazu Machida; Tomoyuki Kawasaki; Mayuko Nishi; Hidenori Akutsu; Akihide Ryo
    Gastroenterology, 2022年04月29日, [査読有り], [筆頭著者], [国際誌]
    英語, 研究論文(学術雑誌)
  • Vaccine-induced humoral response against SARS-CoV-2 dramatically declined but cellular immunity possibly remained at 6 months post BNT162b2 vaccination.
    Hideaki Kato; Kei Miyakawa; Norihisa Ohtake; Yutaro Yamaoka; Satoshi Yajima; Etsuko Yamazaki; Tomoko Shimada; Atsushi Goto; Hideaki Nakajima; Akihide Ryo
    Vaccine, 40, 19, 2652, 2655, 2022年04月26日, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌), To evaluate vaccine-induced humoral and cell-mediated immunity at 6 months after completion of two doses of BNT162b2 vaccination, immunoglobulin G against SARS-CoV-2 spike protein (SP IgG), 50% neutralizing antibody (NT50), and spot-forming cell (SFC) counts were evaluated by interferon-γ releasing ELISpot assay of 98 healthy subjects (median age, 43 years). The geometric mean titers of SP IgG and NT50 decreased from 95.2 (95% confidence interval (CI) 79.8-113.4) to 5.7 (95% CI 4.9-6.7) and from 680.4 (588.0-787.2) to 130.4 (95% CI 104.2-163.1), respectively, at 3 weeks and 6 months after the vaccination. SP IgG titer was negatively correlated with age and alcohol consumption. Spot-forming cell counts at 6 months did not correlate with age, gender, and other parameters of the patients. SP IgG, NT50, and SFC titers were elevated in the breakthrough infected subjects. Although the levels of vaccine-induced antibodies dramatically declined at 6 months after vaccination, a certain degree of cellular immunity was observed irrespective of the age.
  • Detecting SARS-CoV-2 neutralizing immunity: highlighting the potential of split nanoluciferase technology.
    Sundararaj Stanleyraj Jeremiah; Kei Miyakawa; Akihide Ryo
    Journal of molecular cell biology, 2022年04月13日, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌), The COVID-19 pandemic has progressed over two years since its onset causing significant health concerns all over the world and is currently curtailed by mass vaccination. Immunity acquired against SARS-CoV-2 can be following either infection or vaccination. However, one can never be sure whether the acquired immunity is adequate to protect the individual from subsequent infection because of three important factors: individual variations in humoral response dynamics, waning of protective antibodies over time, and the emergence of immune escape mutants. Therefore, a test that can accurately differentiate the protected from the vulnerable is the need of the hour. The plaque reduction neutralization assay is the conventional gold standard test for estimating the titers of neutralizing antibodies that confer protection. However, it has got several drawbacks, which hinder the practical application of this test for widescale usage. Hence, various tests have been developed to detect protective immunity against SARS-CoV-2 that directly or indirectly assess the presence of neutralizing antibodies to SARS-CoV-2 in a lower bio-safety setting. In this review, the pros and cons of the currently available assays are elaborated in detail and special focus is shed on the scope of the novel split nanoluciferase technology for detecting SARS-CoV-2 neutralizing antibodies.
  • Crosstalk between the innate immune system and selective autophagy in hepatitis B virus infection.
    Kei Miyakawa; Sundararaj Stanleyraj Jeremiah; Michinaga Ogawa; Mayuko Nishi; Makoto Ohnishi; Akihide Ryo
    Autophagy, 1, 2, 2022年04月05日, [査読有り], [筆頭著者], [国際誌]
    英語, 研究論文(学術雑誌), Although the involvement of macroautophagy/autophagy in hepatitis B virus (HBV) infection has become clearer recently, whether selective autophagy plays an important role in suppressing HBV remains uncertain. We recently found that LGALS9 (galectin 9) is an interferon (IFN)-inducible protein involved in the suppression of HBV replication. Expression of LGALS9 in HBV-infected cells causes the formation of cytoplasmic puncta that degrade the HBV core protein (HBc) in conjunction with RSAD2/viperin, another IFN-inducible protein. LGALS9 binds to HBc via RSAD2 and promotes the autoubiquitination of RNF13 (ring finger protein 13) to recruit SQSTM1/p62, resulting in the formation of LC3-positive autophagosomes that degrade HBc. Both LGALS9 and RSAD2 are encoded by IFN-stimulated genes that act synergistically to induce HBc proteolysis in HBV-infected hepatocytes in an IFN-dependent manner. These results reveal a crosstalk mechanism between the innate immune system and selective autophagy during viral infection.
  • Evasion of vaccine-induced humoral immunity by emerging sub-variants of SARS-CoV-2.
    Takahiko Koyama; Kei Miyakawa; Reitaro Tokumasu; Sundararaj S Jeremiah; Michiharu Kudo; Akihide Ryo
    Future microbiology, 17, 417, 424, 2022年04月, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌), Background: Emergence of vaccine-escaping SARS-CoV-2 variants is a serious problem for global public health. The currently rampant Omicron has been shown to possess remarkable vaccine escape; however, the selection pressure exerted by vaccines might pave the way for other escape mutants in the near future. Materials & methods: For detection of neutralizing antibodies, the authors used the recently developed HiBiT-based virus-like particle neutralization test system. Sera after vaccination (two doses of Pfizer/BioNTech mRNA vaccine) were used to evaluate the neutralizing activity against various strains of SARS-CoV-2. Results: Beta+R346K, which was identified in the Philippines in August 2021, exhibited the highest vaccine resistance among the tested mutants. Surprisingly, Mu+K417N mutant exhibited almost no decrease in neutralization. Imdevimab retained efficacy against these strains. Conclusions: Mutations outside the receptor-binding domain contributed to vaccine escape. Both genomic surveillance and phenotypic analysis synergistically accelerate identifications of vaccine-escaping strains.
  • MAL Inhibits the Production of HIV-1 Particles by Sequestering Gag to Intracellular Endosomal Compartments
    Kei Miyakawa; Mayuko Nishi; Sundararaj Stanleyraj Jeremiah; Yuko Morikawa; Akihide Ryo
    Frontiers in Virology, 2, Frontiers Media SA, 2022年03月23日, [査読有り], [筆頭著者, 責任著者]
    研究論文(学術雑誌), The host innate immune response is the first line of defense against human immunodeficiency virus (HIV) infection. The type I interferon (IFN) response is a robust anti-viral response that induces the transcription of several IFN-stimulated genes (ISGs). However, the effects of ISGs, particularly on the HIV-1 Gag protein, remain largely unknown. Hence, we screened ISG-encoded proteins by bioluminescence resonance energy transfer to identify the crucial host effectors that suppressed Gag function. Consequently, we identified the transmembrane protein MAL as a Gag-interacting ISG product. In fact, ectopic expression of MAL substantially inhibited the production of HIV-1 particles, leading to the translocation, accumulation, and eventual lysosomal degradation of Gag in the host endosomal compartments. Owing to the conserved N-terminal region of MAL, which specifically interacts with HIV-1 Gag, this particular antiviral function of MAL targeting Gag is also conserved among orthologs of various animal species. Notably, the antiviral activity of MAL was partially antagonized by the viral accessory protein Nef, as it interfered with the interaction between MAL and Gag. Therefore, this study reveals a previously unidentified antiviral function of MAL and its viral counteraction. It also sheds new light on therapeutic strategies against HIV-1 infection based on the intrinsic antiviral immunity of host cells.
  • Phosphopeptide enrichment using Phos-tag technology reveals functional phosphorylation of the nucleocapsid protein of SARS-CoV-2.
    Yoko Ino; Mayuko Nishi; Yutaro Yamaoka; Kei Miyakawa; Sundararaj Stanleyraj Jeremiah; Makoto Osada; Yayoi Kimura; Akihide Ryo
    Journal of proteomics, 255, 104501, 104501, 2022年03月20日, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌), Phosphorylation of viral proteins serves as a regulatory mechanism during the intracellular life cycle of infected viruses. There is therefore a pressing need to develop a method to efficiently purify and enrich phosphopeptides derived from viral particles in biological samples. In this study, we utilized Phos-tag technology to analyze the functional phosphorylation of the nucleocapsid protein (N protein; NP) of severe respiratory syndrome coronavirus 2 (SARS-CoV-2). Viral particles were collected from culture supernatants of SARS-CoV-2-infected VeroE6/TMPRSS2 cells by ultracentrifugation, and phosphopeptides were purified by Phos-tag magnetic beads for LC-MS/MS analysis. Analysis revealed that NP was reproducibly phosphorylated at serine 79 (Ser79). Multiple sequence alignment and phylogenetic analysis showed that the Ser79 was a distinct phospho-acceptor site in SARS-CoV-2 but not in other beta-coronaviruses. We also found that the prolyl-isomerase Pin1 bound to the phosphorylated Ser79 in NP and positively regulated the production of viral particles. These results suggest that SARS-CoV-2 may have acquired the potent virus-host interaction during its evolution mediated by viral protein phosphorylation. Moreover, Phos-tag technology can provide a useful means for analyzing the functional phosphorylation of viral proteins. SIGNIFICANCE: In this study, we aimed to investigate the functional phosphorylation of SARS-CoV-2 NP. For this purpose, we used Phos-tag technology to purify and enrich virus-derived phosphopeptides with high selectivity and reproducibility. This method can be particularly useful in analyzing viral phosphopeptides from cell culture supernatants that often contain high concentrations of fetal bovine serum and supplements. We newly identified an NP phosphorylation site at Ser79, which is important for Pin1 binding. Furthermore, we showed that the interaction between Pin1 and phosphorylated NP could enhance viral replication in a cell culture model.
  • Antibody titers against the Alpha, Beta, Gamma, and Delta variants of SARS-CoV-2 induced by BNT162b2 vaccination measured using automated chemiluminescent enzyme immunoassay.
    Hideaki Kato; Kei Miyakawa; Norihisa Ohtake; Hirofumi Go; Yutaro Yamaoka; Satoshi Yajima; Tomoko Shimada; Atsushi Goto; Hideaki Nakajima; Akihide Ryo
    Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy, 28, 2, 273, 278, 2022年02月, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌), BACKGROUND: Levels of 50% neutralizing titer (NT50) reflect the a vaccine-induced humoral immunity after the vaccination against the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). Measurements of NT50 are difficult to implement in large quantities. A high-throughput laboratory test is expected for determining the level of herd immunity against SARS-CoV-2. METHODS: We analyzed samples from 168 Japanese healthcare workers who had completed two doses of the BNT162b2 vaccine. We analyzed immunoglobulin G (IgG) index values against spike protein (SP) using automated chemiluminescent enzyme immunoassay system AIA-CL and analyzed the background factors affecting antibody titer. SP IgG index was compared with 50% neutralization titers. RESULTS: The median SP IgG index values of the subjects (mean age = 43 years; 75% female) were 0.1, 1.35, 60.80, and 97.35 before and at 2, 4, and 6 weeks after the first dose, respectively. At 4 and 6 weeks after the first dose, SP IgG titers were found to have positive correlation with NT50 titer (r = 0.7535 in 4 weeks; r = 0.4376 in 6 weeks). Proportions of the SP IgG index values against the Alpha, Beta, Gamma, and Delta variants compared with the original strain were 2.029, 0.544, 1.017, and 0.6096 respectively. Older age was associated with lower SP IgG titer index 6 weeks after the first dose. CONCLUSIONS: SP IgG index values were rised at 3 weeks after two doses of BNT162b2 vaccination and have positive correlation with NT50. SP IgG index values were lower in the older individuals and against Beta and Delta strain.
  • Persistence of Robust Humoral Immune Response in Coronavirus Disease 2019 Convalescent Individuals Over 12 Months After Infection.
    Kei Miyakawa; Sousuke Kubo; Sundararaj Stanleyraj Jeremiah; Hirofumi Go; Yutaro Yamaoka; Norihisa Ohtake; Hideaki Kato; Satoshi Ikeda; Takahiro Mihara; Ikuro Matsuba; Naoko Sanno; Masaaki Miyakawa; Masaharu Shinkai; Tomoyuki Miyazaki; Takashi Ogura; Shuichi Ito; Takeshi Kaneko; Kouji Yamamoto; Atsushi Goto; Akihide Ryo
    Open forum infectious diseases, 9, 2, ofab626, 2022年02月, [査読有り], [筆頭著者], [国際誌]
    英語, 研究論文(学術雑誌), Background: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection elicits varying degrees of protective immunity conferred by neutralizing antibodies (nAbs). In this study, we report the persistence of nAb responses over 12 months after infection despite their decreasing trend noticed from 6 months. Methods: The study included sera from 497 individuals who had been infected with SARS-CoV-2 between January and August 2020. Samples were collected at 6 and 12 months after onset. The titers of immunoglobulin (Ig)G to the viral nucleocapsid protein (NP) and receptor-binding domain (RBD) of the spike protein were measured by chemiluminescence enzyme immunoassay. The nAb titer was determined using lentivirus-based pseudovirus or authentic virus. Results: Antibody titers of NP-IgG, RBD-IgG, and nAbs were higher in severe and moderate cases than in mild cases at 12 months after onset. Although the nAb levels were likely to confer adequate protection against wild-type viral infection, the neutralization activity to recently circulating variants in some of the mild cases (~30%) was undermined, implying the susceptibility to reinfection with the variants of concerns (VOCs). Conclusions: Coronavirus disease 2019 convalescent individuals have robust humoral immunity even at 12 months after infection albeit that the medical history and background of patients could affect the function and dynamics of antibody response to the VOCs.
  • Establishment of monoclonal antibodies broadly neutralize infection of hepatitis B virus.
    He Zhang; Yumi Itoh; Tatsuya Suzuki; Kan-Ichiro Ihara; Tomohisa Tanaka; Saori Haga; Hajime Enatsu; Maho Yumiya; Mari Kimura; Akira Takada; Daiki Itoh; Yuri Shibazaki; Shuto Nakao; Sachiyo Yoshio; Kei Miyakawa; Yuki Miyamoto; Hanae Sasaki; Tadahiro Kajita; Masaya Sugiyama; Masashi Mizokami; Taro Tachibana; Akihide Ryo; Kohji Moriishi; Eiji Miyoshi; Tatsuya Kanto; Toru Okamoto; Yoshiharu Matsuura
    Microbiology and immunology, 66, 4, 179, 192, 2022年01月27日, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌), Antibodies against hepatitis B virus S protein can protect against hepatitis B virus (HBV) infection. Therefore, hepatitis B immunoglobulin (HBIG), which contains HBsAb, is used clinically as a therapy for HBV infection. In this study, we obtained a series of monoclonal antibodies that recognize multiple HBV genotypes. All the antibodies recognized conformational epitopes of S protein, but not linear epitopes. Several antibodies neutralized HBV infection and exhibited strong affinities and neutralizing activities. Antigenic epitope analysis demonstrated that they recognized residue Ile152 of S protein, which is localized outside the "a" determinant. Ile152 is highly conserved, and a mutation in this residue resulted in reduced expression of large hepatitis B surface proteins (L protein), suggesting that the amino acid at this position is involved in the expression of L protein. In addition, the antibodies neutralized the infection of hepatitis D virus possessing a Gly145 mutation to Arg in S protein, which is a well-known escape mutation against HBIG treatment. Using mouse monoclonal antibodies, we successfully established a humanized antibody possessing affinities and neutralizing activities similar to those of the original mouse antibody. The antibodies generated in this study may have potential for use in alternative antibody therapies for HBV infection. This article is protected by copyright. All rights reserved.
  • Galectin-9 restricts hepatitis B virus replication via p62/SQSTM1-mediated selective autophagy of viral core proteins.
    Kei Miyakawa; Mayuko Nishi; Michinaga Ogawa; Satoko Matsunaga; Masaya Sugiyama; Hironori Nishitsuji; Hirokazu Kimura; Makoto Ohnishi; Koichi Watashi; Kunitada Shimotohno; Takaji Wakita; Akihide Ryo
    Nature communications, 13, 1, 531, 531, 2022年01月27日, [査読有り], [筆頭著者], [国際誌]
    英語, 研究論文(学術雑誌), Autophagy has been linked to a wide range of functions, including a degradative process that defends host cells against pathogens. Although the involvement of autophagy in HBV infection has become apparent, it remains unknown whether selective autophagy plays a critical role in HBV restriction. Here, we report that a member of the galectin family, GAL9, directs the autophagic degradation of HBV HBc. BRET screening revealed that GAL9 interacts with HBc in living cells. Ectopic expression of GAL9 induces the formation of HBc-containing cytoplasmic puncta through interaction with another antiviral factor viperin, which co-localized with the autophagosome marker LC3. Mechanistically, GAL9 associates with HBc via viperin at the cytoplasmic puncta and enhanced the auto-ubiquitination of RNF13, resulting in p62 recruitment to form LC3-positive autophagosomes. Notably, both GAL9 and viperin are type I IFN-stimulated genes that act synergistically for the IFN-dependent proteolysis of HBc in HBV-infected hepatocytes. Collectively, these results reveal a previously undescribed antiviral mechanism against HBV in infected cells and a form of crosstalk between the innate immune system and selective autophagy in viral infection.
  • Molecular and Epidemiological Characterization of Emerging Immune-Escape Variants of SARS-CoV-2.
    Kei Miyakawa; Sundararaj Stanleyraj Jeremiah; Yutaro Yamaoka; Takahiko Koyama; Reitaro Tokumasu; Michiharu Kudo; Hideaki Kato; Akihide Ryo
    Frontiers in medicine, 9, 811004, 811004, 2022年, [査読有り], [責任著者], [国際誌]
    英語, 研究論文(学術雑誌), The successive emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants has presented a major challenge in the management of the coronavirus disease (COVID-19) pandemic. There are growing concerns regarding the emerging variants escaping vaccines or therapeutic neutralizing antibodies. In this study, we conducted an epidemiological survey to identify SARS-CoV-2 variants that are sporadically proliferating in vaccine-advanced countries. Subsequently, we created HiBiT-tagged virus-like particles displaying spike proteins derived from the variants to analyze the neutralizing efficacy of the BNT162b2 mRNA vaccine and several therapeutic antibodies. We found that the Mu variant and a derivative of the Delta strain with E484K and N501Y mutations significantly evaded vaccine-elicited neutralizing antibodies. This trend was also observed in the Beta and Gamma variants, although they are currently not prevalent. Although 95.2% of the vaccinees exhibited prominent neutralizing activity against the prototype strain, only 73.8 and 78.6% of the vaccinees exhibited neutralizing activity against the Mu and the Delta derivative variants, respectively. A long-term analysis showed that 88.8% of the vaccinees initially exhibited strong neutralizing activity against the currently circulating Delta strain; the number decreased to 31.6% for the individuals at 6 months after vaccination. Notably, these variants were shown to be resistant to several therapeutic antibodies. Our findings demonstrate the differential neutralization efficacy of the COVID-19 vaccine and monoclonal antibodies against circulating variants, suggesting the need for pandemic alerts and booster vaccinations against the currently prevalent variants.
  • 【新型コロナウイルス感染症の最新動向】新型コロナウイルス感染症に対する抗原検査法
    山岡 悠太郎; 宮川 敬; 森田 武志; 梁 明秀
    感染制御と予防衛生, 5, 2, 60, 66, (株)メディカルレビュー社, 2021年12月
    日本語
  • HBx-induced degradation of Smc5/6 complex impairs homologous recombination-mediated repair of damaged DNA.
    Kazuma Sekiba; Motoyuki Otsuka; Kazuyoshi Funato; Yu Miyakawa; Eri Tanaka; Takahiro Seimiya; Mari Yamagami; Takeya Tsutsumi; Kazuya Okushin; Kei Miyakawa; Akihide Ryo; Kazuhiko Koike
    Journal of hepatology, 76, 1, 53, 62, 2021年08月31日, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌), BACKGROUND & AIMS: HBV causes hepatocellular carcinoma (HCC). While it was recently shown that the ability of HBV X protein (HBx) to impair the Smc5/6 (structural maintenance of chromosome 5/6) complex is important for viral transcription, HBx is also a potent driver of HCC. However, the mechanism by which HBx expression induces hepatocarcinogenesis is unclear. METHODS: Degradation of the Smc5/6 complex and accumulation of DNA damage were observed in both in vivo and in vitro HBV infection models. Rescue experiments were performed using nitazoxanide (NTZ), which inhibits degradation of the Smc5/6 complex by HBx. RESULTS: HBx-triggered degradation of the Smc5/6 complex causes impaired homologous recombination (HR) repair of DNA double-strand breaks (DSBs), leading to cellular transformation. We found that DNA damage accumulated in the liver tissue of HBV-infected humanized chimeric mice, HBx-transgenic mice, and human tissues. HBx suppressed the HR repair of DSBs, including that induced by the CRISPR-Cas9 system, in an Smc5/6-dependent manner, which was rescued by restoring the Smc5/6 complex. NTZ restored HR repair in, and colony formation by, HBx-expressing cells. CONCLUSIONS: Degradation of the Smc5/6 complex by HBx increases viral transcription and promotes cellular transformation by impairing HR repair of DSBs. LAY SUMMARY: The hepatitis B virus expresses a regulatory protein called HBV X protein (or HBx). This protein degrades the Smc5/6 complex in human hepatocytes, which is essential for viral replication. We found that this process also plays a key role in the accumulation of DNA damage, which contributes to HBx-mediated tumorigenesis.
  • Rapid detection of neutralizing antibodies to SARS-CoV-2 variants in post-vaccination sera.
    Kei Miyakawa; Jeremiah Sundararaj Stanleyraj; Hideaki Kato; Yutaro Yamaoka; Hirofumi Go; Satoshi Yajima; Tomoko Shimada; Takahiro Mihara; Atsushi Goto; Takeharu Yamanaka; Akihide Ryo
    Journal of molecular cell biology, 13, 12, 918, 920, 2021年08月27日, [査読有り], [筆頭著者], [国際誌]
    英語, 研究論文(学術雑誌), The uncontrolled spread of the COVID-19 pandemic has led to the emergence of different SARS-CoV-2 variants across the globe. The ongoing global vaccination strategy to curtail the COVID-19 juggernaut, is threatened by the rapidly spreading Variants of Concern (VOC) and other regional mutants, which are less responsive to neutralization by infection or vaccine derived antibodies. We have previously developed the hiVNT system which detects SARS-CoV-2 neutralizing antibodies in sera in less than three hours. In this study, we modify the hiVNT for rapid qualitative screening of neutralizing antibodies (nAb) to multiple VOC of SARS-CoV-2, and assess the neutralizing efficacy of the BNT162b2 mRNA vaccine on seven epidemiologically relevant SARS-CoV-2 variants. Here we show that the BNT162b2 mRNA vaccine can activate humoral immunity against the major SARS-CoV-2 mutants that are currently in circulation. Albeit a small sample size, we observed that one dose of vaccine was sufficient to elicit a protective humoral response in previously infected people. Using a panel of seven SARS-CoV-2 variants and a single prototype virus, our modified hiVNT would be useful for large-scale community wide testing to detect protective immunity that may confer vaccine/immune passport in the ongoing COVID-19 pandemic.
  • Capsid Allosteric Modulators Enhance the Innate Immune Response in Hepatitis B Virus-Infected Hepatocytes During Interferon Administration.
    Keisuke Fukutomi; Hayato Hikita; Kazuhiro Murai; Tasuku Nakabori; Akiyoshi Shimoda; Makoto Fukuoka; Takuo Yamai; Yuichiro Higuchi; Kei Miyakawa; Hiroshi Suemizu; Akihide Ryo; Ryoko Yamada; Takahiro Kodama; Ryotaro Sakamori; Tomohide Tatsumi; Tetsuo Takehara
    Hepatology communications, 6, 2, 281, 296, 2021年08月25日, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌), Capsid allosteric modulators (CAMs) inhibit the encapsidation of hepatitis B virus (HBV) pregenomic RNA (pgRNA), which contains a pathogen-associated molecular pattern motif. However, the effect of CAMs on the innate immune response of HBV-infected hepatocytes remains unclear, and we examined this effect in this study. Administration of a CAM compound, BAY41-4109 (BAY41), to HBV-infected primary human hepatocytes (PHHs) did not change the total cytoplasmic pgRNA levels but significantly reduced intracapsid pgRNA levels, suggesting that BAY41 increased extracapsid pgRNA levels in the cytoplasm. BAY41 alone did not change the intracellular interferon (IFN)-stimulated gene (ISG) expression levels. However, BAY41 enhanced antiviral ISG induction by IFN-α in HBV-infected PHHs but did not change ISG induction by IFN-α in uninfected PHHs. Compared with BAY41 or IFN-α alone, coadministration of BAY41 and IFN-α significantly suppressed extracellular HBV-DNA levels. HBV-infected human liver-chimeric mice were treated with vehicle, BAY41, pegylated IFN-α (pegIFN-α), or BAY41 and pegIFN-α together. Compared with the vehicle control, pegIFN-α highly up-regulated intrahepatic ISG expression levels, but BAY41 alone did not change these levels. The combination of BAY41 and pegIFN-α further enhanced intrahepatic antiviral ISG expression, which was up-regulated by pegIFNα. The serum HBV-DNA levels in mice treated with the combination of BAY41 and pegIFN-α were the lowest observed in all the groups. Conclusion: CAMs enhance the host IFN response when combined with exogenous IFN-α, likely due to increased cytoplasmic extracapsid pgRNA.
  • All-Trans Retinoic Acid Exhibits Antiviral Effect against SARS-CoV-2 by Inhibiting 3CLpro Activity.
    Takeshi Morita; Kei Miyakawa; Sundararaj Stanleyraj Jeremiah; Yutaro Yamaoka; Mitsuru Sada; Tomoko Kuniyoshi; Jinwei Yang; Hirokazu Kimura; Akihide Ryo
    Viruses, 13, 8, 2021年08月23日, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌), The pandemic of COVID-19 caused by SARS-CoV-2 continues to spread despite the global efforts taken to control it. The 3C-like protease (3CLpro), the major protease of SARS-CoV-2, is one of the most interesting targets for antiviral drug development because it is highly conserved among SARS-CoVs and plays an important role in viral replication. Herein, we developed high throughput screening for SARS-CoV-2 3CLpro inhibitor based on AlphaScreen. We screened 91 natural product compounds and found that all-trans retinoic acid (ATRA), an FDA-approved drug, inhibited 3CLpro activity. The 3CLpro inhibitory effect of ATRA was confirmed in vitro by both immunoblotting and AlphaScreen with a 50% inhibition concentration (IC50) of 24.7 ± 1.65 µM. ATRA inhibited the replication of SARS-CoV-2 in VeroE6/TMPRSS2 and Calu-3 cells, with IC50 = 2.69 ± 0.09 µM in the former and 0.82 ± 0.01 µM in the latter. Further, we showed the anti-SARS-CoV-2 effect of ATRA on the currently circulating variants of concern (VOC); alpha, beta, gamma, and delta. These results suggest that ATRA may be considered as a potential therapeutic agent against SARS-CoV-2.
  • Development of highly sensitive and rapid antigen detection assay for diagnosis of COVID-19 utilizing optical waveguide immunosensor.
    Rikako Funabashi; Kei Miyakawa; Yutaro Yamaoka; Seiko Yoshimura; Satoshi Yamane; Sundararaj Stanleyraj Jeremiah; Kohei Shimizu; Hiroki Ozawa; Chiharu Kawakami; Shuzo Usuku; Nobuko Tanaka; Etsuko Yamazaki; Hirokazu Kimura; Hideki Hasegawa; Akihide Ryo
    Journal of molecular cell biology, 13, 10, 763, 766, 2021年06月24日, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌)
  • Highly specific monoclonal antibodies and epitope identification against SARS-CoV-2 nucleocapsid protein for antigen detection tests.
    Yutaro Yamaoka#; Kei Miyakawa#; Sundararaj Stanleyraj Jeremiah; Rikako Funabashi; Koji Okudela; Sayaka Kikuchi; Junichi Katada; Atsuhiko Wada; Toshiki Takei; Mayuko Nishi; Kohei Shimizu; Hiroki Ozawa; Shuzo Usuku; Chiharu Kawakami; Nobuko Tanaka; Takeshi Morita; Hiroyuki Hayashi; Hideaki Mitsui; Keita Suzuki; Daisuke Aizawa; Yukihiro Yoshimura; Tomoyuki Miyazaki; Etsuko Yamazaki; Tadaki Suzuki; Hirokazu Kimura; Hideaki Shimizu; Nobuhiko Okabe; Hideki Hasegawa; Akihide Ryo
    Cell Reports Medicine, 2, 6, 100311, 100311, 2021年06月15日, [査読有り], [筆頭著者], [国際誌]
    英語, 研究論文(学術雑誌), The ongoing coronavirus disease 2019 (COVID-19) pandemic is a major global public health concern. Although rapid point-of-care testing for detecting viral antigen is important for management of the outbreak, the current antigen tests are less sensitive than nucleic acid testing. In our current study, we produce monoclonal antibodies (mAbs) that exclusively react with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and exhibit no cross-reactivity with other human coronaviruses, including SARS-CoV. Molecular modeling suggests that the mAbs bind to epitopes present on the exterior surface of the nucleocapsid, making them suitable for detecting SARS-CoV-2 in clinical samples. We further select the optimal pair of anti-SARS-CoV-2 nucleocapsid protein (NP) mAbs using ELISA and then use this mAb pair to develop immunochromatographic assay augmented with silver amplification technology. Our mAbs recognize the variants of concern (501Y.V1-V3) that are currently in circulation. Because of their high performance, the mAbs of this study can serve as good candidates for developing antigen detection kits for COVID-19.
  • 【感染症と香粧品科学】新型コロナウイルスに対する阻害剤スクリーニング法の開発とその応用
    森田 武志; 宮川 敬; 山岡 悠太郎; 國吉 智子; 梁 明秀
    FRAGRANCE JOURNAL, 49, 6, 32, 38, フレグランスジャーナル社, 2021年06月
    日本語
  • A case of multisystem inflammatory syndrome in children in a japanese boy: with discussion of cytokine profile.
    Sayaka Fukuda; Mio Kaneta; Mayuko Miyake; Takashi Ohya; Kei Miyakawa; Mari Iwamoto; Shuichi Ito
    Modern rheumatology case reports, 5, 2, 1, 11, 2021年04月27日, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌), The new disease concept of multisystem inflammatory syndrome in children (MIS-C), which is a systemic inflammatory syndrome with multiple organ involvement after SARS-CoV2 infection, was established in 2020. MIS-C is common in Hispanic and black children in Europe and North America, with few reports in East Asians. A significant portion of patients with MIS-C develop Kawasaki disease (KD)-like symptoms. Therefore, differential diagnosis is challenging, especially in East Asia, where KD is most prevalent. No Japanese cases have been reported in the literatures so far. We report a case of MIS-C in Japan with KD-like symptoms. A 9-year-old Japanese boy, who was infected with SARS-CoV2 1 month previously along with his family, was admitted to our hospital owing to fever for 6 days and erythema mainly in the groyne and pubic area. He also had conjunctivitis, strawberry tongue, and diarrhoea. His laboratory findings were as follows: WBC, 12,840/µL (lymphocytes, 4%); CRP, 22.6 mg/dL, pro-calcitonin, 1.8 ng/mL (normal, <0.50 ng/mL); NT pro-BNP, 7627 pg/mL (<125 pg/mL); and troponin T, 0.14 ng/mL (<0.01 ng/mL). His cardiac function was normal. We initially diagnosed him with KD. His fever rapidly resolved with intravenous immunoglobulin and there were no coronary artery lesions. Desquamation of the fingers was observed later. Finally, a history of SARS-COV2 infection, his age, atypical skin rash, elevation of markers of inflammation and heart failure, and lymphopenia suggested the diagnosis of MIS-C rather than KD. Differentiation between KD and MIS-C is necessary even in Japan, especially in patients with atypical features of KD.
  • 【新型コロナウイルス感染症UP-TO-DATE 2021】新型コロナウイルス感染症の病態と免疫
    久保 創介; 山岡 悠太郎; 宮川 敬; 梁 明秀
    感染制御と予防衛生, 5, 1, 10, 17, (株)メディカルレビュー社, 2021年04月
    日本語
  • 新型コロナウイルス感染症(COVID-19)の診断法の実際と開発状況
    宮川 敬; 梁 明秀
    循環器内科, 89, 2, 184, 190, (有)科学評論社, 2021年02月
    日本語
  • 【新型コロナウイルスの最前線〜未知なる感染症にどう立ち向かうか〜】新型コロナウイルスの抗原・抗体検査法
    山岡 悠太郎; 宮川 敬; 梁 明秀
    神奈川県公衆衛生学会誌, 66, 66, 22, 25, 神奈川県公衆衛生協会, 2021年02月
    日本語
  • 【COVID-19の病態・診断・治療 現場の知恵とこれからの羅針盤】(III章)各論:疫学・診断・治療 COVID-19の診断方法 基礎の立場から
    久保 創介; 宮川 敬; 梁 明秀
    呼吸器ジャーナル, 別冊, 53, 61, (株)医学書院, 2021年01月
    日本語
  • Combining IL-6 and SARS-CoV-2 RNAaemia-based risk stratification for fatal outcomes of COVID-19.
    Ryo Saji; Mototsugu Nishii; Kazuya Sakai; Kei Miyakawa; Yutaro Yamaoka; Tatsuma Ban; Takeru Abe; Yutaro Ohyama; Kento Nakajima; Taro Hiromi; Reo Matsumura; Naoya Suzuki; Hayato Taniguchi; Tsuyoshi Otsuka; Yasufumi Oi; Fumihiro Ogawa; Munehito Uchiyama; Kohei Takahashi; Masayuki Iwashita; Yayoi Kimura; Satoshi Fujii; Ryosuke Furuya; Tomohiko Tamura; Akihide Ryo; Ichiro Takeuchi
    PloS one, 16, 8, e0256022, 2021年, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌), BACKGROUND: The coronavirus disease 2019 (COVID-19) pandemic rapidly increases the use of mechanical ventilation (MV). Such cases further require extracorporeal membrane oxygenation (ECMO) and have a high mortality. OBJECTIVE: We aimed to identify prognostic biomarkers pathophysiologically reflecting future deterioration of COVID-19. METHODS: Clinical, laboratory, and outcome data were collected from 102 patients with moderate to severe COVID-19. Interleukin (IL)-6 level and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) RNA copy number in plasma were assessed with ELISA kit and quantitative PCR. RESULTS: Twelve patients died or required ECMO owing to acute respiratory distress syndrome despite the use of MV. Among various variables, a ratio of oxygen saturation to fraction of inspired oxygen (SpO2/FiO2), IL-6, and SARS-CoV-2 RNA on admission before intubation were strongly predictive of fatal outcomes after the MV use. Moreover, among these variables, combining SpO2/FiO2, IL-6, and SARS-CoV-2 RNA showed the highest accuracy (area under the curve: 0.934). In patients with low SpO2/FiO2 (< 261), fatal event-rate after the MV use at the 30-day was significantly higher in patients with high IL-6 (> 49 pg/mL) and SARS-CoV-2 RNAaemia (> 1.5 copies/μL) compared to those with high IL-6 or RNAaemia or without high IL-6 and RNAaemia (88% vs. 22% or 8%, log-rank test P = 0.0097 or P < 0.0001, respectively). CONCLUSIONS: Combining SpO2/FiO2 with high IL-6 and SARS-CoV-2 RNAaemia which reflect hyperinflammation and viral overload allows accurately and before intubation identifying COVID-19 patients at high risk for ECMO use or in-hospital death despite the use of MV.
  • Cleavage of TANK-Binding Kinase 1 by HIV-1 Protease Triggers Viral Innate Immune Evasion.
    Sundararaj Stanleyraj Jeremiah; Kei Miyakawa; Satoko Matsunaga; Mayuko Nishi; Ayumi Kudoh; Akinori Takaoka; Tatsuya Sawasaki; Akihide Ryo
    Frontiers in microbiology, 12, 643407, 643407, 2021年, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌), Type-I interferons (IFN-I) are the innate immune system's principal defense against viral infections. Human immunodeficiency virus-1 (HIV-1) has evolved several ways to suppress or evade the host's innate immunity in order to survive and replicate to sustain infection. Suppression of IFN-I is one among the multiple escape strategies used by HIV-1 to prevent its clearance. HIV-1 protease which helps in viral maturation has also been observed to cleave host cellular protein kinases. In this study we performed a comprehensive screening of a human kinase library using AlphaScreen assay and identified that TANK binding kinase-1 (TBK1) was cleaved by HIV-1 protease (PR). We demonstrate that PR cleaved TBK1 fails to phosphorylate IFN regulatory factor 3 (IRF3), thereby reducing the IFN-I promoter activity and further reveal that the PR mediated suppression of IFN-I could be counteracted by protease inhibitors (PI) in vitro. We have also revealed that mutations of HIV-1 PR that confer drug resistance to PIs reduce the enzyme's ability to cleave TBK1. The findings of this study unearth a direct link between HIV-1 PR activity and evasion of innate immunity by the virus, the possible physiological relevance of which warrants to be determined.
  • Sustained Neutralizing Antibodies 6 Months Following Infection in 376 Japanese COVID-19 Survivors.
    Atsushi Goto; Hirofumi Go; Kei Miyakawa; Yutaro Yamaoka; Norihisa Ohtake; Sousuke Kubo; Sundararaj Stanleyraj Jeremiah; Takahiro Mihara; Kotaro Senuki; Tomoyuki Miyazaki; Satoshi Ikeda; Takashi Ogura; Hideaki Kato; Ikuro Matsuba; Naoko Sanno; Masaaki Miyakawa; Haruo Ozaki; Masakazu Kikuoka; Yasuo Ohashi; Akihide Ryo; Takeharu Yamanaka
    Frontiers in microbiology, 12, 661187, 661187, 2021年, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌), Objective: There is scarce evidence regarding the long-term persistence of neutralizing antibodies among coronavirus disease 2019 (COVID-19) survivors. This study determined neutralizing antibody titers (NT50) and antibodies against spike protein (SP) or nucleocapsid protein (NP) antigens approximately 6 months after the diagnosis of COVID-19. Methods: COVID-19 survivors in Japan were recruited. Serum samples and data related to patients' characteristics and COVID-19 history were collected. NT50 and titers of antibodies against NP and SP antigens were measured at 20-32 weeks after the first positive severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) test results. Factors associated with NT50 were identified using the multivariable linear regression and the correlations among NT50 and titers of immunoglobulin G (IgG) and total immunoglobulins (Igs) against NP and SP were assessed by Spearman's correlation. Results: Among 376 participants (median [range] days after testing positive for SARS-CoV-2, 180 (147-224); median [range] years of age, 50 (20-78); 188 [50%] male), most tested positive for NT50 (n = 367, 98%), SP-IgG (n = 344, 91%), SP-total Ig (n = 369, 98%), NP-IgG (n = 314, 84%), and NP-total Ig (n = 365, 97%). Regression analysis indicated that higher BMI, fever, and the requirement of mechanical ventilation or extracorporeal membrane oxygenation were significantly associated with higher NT50. Anti-SP antibodies correlated moderately with NT50 (Spearman's correlation: 0.63 for SP IgG; 0.57 for SP-total Ig), while the correlation was weak for anti-NP antibodies (0.37 for NP IgG; 0.32 for NP-total Ig). Conclusions: Most COVID-19 survivors had sustained neutralizing antibodies and tested positive for SP-total Ig and NP-total Ig approximately 6 months after infection.
  • Potent antiviral effect of silver nanoparticles on SARS-CoV-2.
    Sundararaj S Jeremiah; Kei Miyakawa; Takeshi Morita; Yutaro Yamaoka; Akihide Ryo
    Biochemical and biophysical research communications, 533, 1, 195, 200, 2020年11月26日, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌), The pandemic of COVID-19 is spreading unchecked due to the lack of effective antiviral measures. Silver nanoparticles (AgNP) have been studied to possess antiviral properties and are presumed to inhibit SARS-CoV-2. Due to the need for an effective agent against SARS-CoV-2, we evaluated the antiviral effect of AgNPs. We evaluated a plethora of AgNPs of different sizes and concentration and observed that particles of diameter around 10 nm were effective in inhibiting extracellular SARS-CoV-2 at concentrations ranging between 1 and 10 ppm while cytotoxic effect was observed at concentrations of 20 ppm and above. Luciferase-based pseudovirus entry assay revealed that AgNPs potently inhibited viral entry step via disrupting viral integrity. These results indicate that AgNPs are highly potent microbicides against SARS-CoV-2 but should be used with caution due to their cytotoxic effects and their potential to derange environmental ecosystems when improperly disposed.
  • Zika virus protease induces caspase-independent pyroptotic cell death by directly cleaving gasdermin D.
    Yutaro Yamaoka; Satoko Matsunaga; Sundararaj S Jeremiah; Mayuko Nishi; Kei Miyakawa; Takeshi Morita; Hajera Khatun; Hideaki Shimizu; Nobuhiko Okabe; Hirokazu Kimura; Hideki Hasegawa; Akihide Ryo
    Biochemical and biophysical research communications, 534, 666, 671, 2020年11月15日, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌), The association of Zika virus (ZIKV) infection with a congenital malformation in fetuses, neurological, and other systemic complications in adults have brought significant global health emergency. ZIKV targets nerve cells in the brain and causes cell death, such as pyroptosis, leading to neuroinflammation. Here we described a novel mechanism of pyroptosis caused by ZIKV protease. We found that ZIKV protease directly cleaved the GSDMD into N-terminal fragment (1-249) leading to pyroptosis in a caspase-independent manner, suggesting a direct mechanism of ZIKV-induced cell death and subsequent inflammation. Our findings might shed new light to explore the pathogenesis of ZIKV infections where ZIKV protease might be a suitable target for the development of antiviral agents.
  • HIV複製を制御する宿主タンパク質の探索とそのメカニズム解析
    宮川 敬
    横浜医学, 71, 4, 603, 607, 横浜市立大学医学会, 2020年10月, [責任著者]
    日本語
  • Development of Monoclonal Antibodies and Antigen-Capture ELISA for Human Parechovirus Type 3.
    Keiko Goto; Yutaro Yamaoka; Hajera Khatun; Kei Miyakawa; Mayuko Nishi; Noriko Nagata; Toshikazu Yanaoka; Hirokazu Kimura; Akihide Ryo
    Microorganisms, 8, 9, 2020年09月19日, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌), Human parechovirus type 3 (HPeV3) is an etiologic agent of respiratory diseases, meningitis, and sepsis-like illness in both infants and adults. Monoclonal antibodies (mAbs) can be a promising diagnostic tool for antigenic diseases such as virus infection, as they offer a high specificity toward a specific viral antigen. However, to date, there is no specific mAb available for the diagnosis of HPeV3 infection. In this study, we developed and characterized mAbs specific for HPeV3 capsid protein VP0. We used cell-free, wheat germ-synthesized viral VP0 protein for immunizing BALB/c mice to generate hybridomas. From the resultant hybridoma clones, we selected nine clones producing mAbs reactive to the HPeV3-VP0 antigen, based on enzyme-linked immunosorbent assay (ELISA). Epitope mapping showed that these mAbs recognized three distinct domains in HPeV3 VP0. Six mAbs recognized HPeV3 specifically and the other three mAbs showed cross-reactivity with other HPeVs. Using the HPeV3-specific mAbs, we then developed an ELISA for viral antigen detection that could be reliably used for laboratory diagnosis of HPeV3. This ELISA system exhibited no cross-reactivity with other related viruses. Our newly developed mAbs would, thus, provide a useful set of tools for future research and ensure HPeV3-specific diagnosis.
  • Rapid quantitative screening assay for SARS-CoV-2 neutralizing antibodies using HiBiT-tagged virus-like particles.
    Kei Miyakawa; Sundararaj Stanleyraj Jeremiah; Norihisa Ohtake; Satoko Matsunaga; Yutaro Yamaoka; Mayuko Nishi; Takeshi Morita; Ryo Saji; Mototsugu Nishii; Hirokazu Kimura; Hideki Hasegawa; Ichiro Takeuchi; Akihide Ryo
    Journal of molecular cell biology, 12, 12, 987, 990, 2020年09月15日, [査読有り], [筆頭著者], [国際誌]
    英語, 研究論文(学術雑誌)
  • SIRT1 enhances hepatitis virus B transcription independent of hepatic autophagy.
    Takuo Yamai; Hayato Hikita; Makoto Fukuoka; Keisuke Fukutomi; Kazuhiro Murai; Tasuku Nakabori; Ryoko Yamada; Kei Miyakawa; Kohei Watashi; Akihide Ryo; Takahiro Kodama; Ryotaro Sakamori; Tomohide Tatsumi; Tetsuo Takehara
    Biochemical and biophysical research communications, 527, 1, 64, 70, 2020年06月18日, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌), Autophagy is an intracellular process that can lead to the degradation of malfunctioned proteins and damaged organelles to maintain homeostasis during cellular stress. Here, we evaluated the change in hepatitis B virus (HBV) production by regulating hepatic autophagy in HBV-producing cells. We examined focusing on a relation with a positive autophagy regulator, sirtuin1 (SIRT1). Starvation and rapamycin treatment induced autophagy with increasing SIRT1 protein, HBc protein and pregenomic RNA (pgRNA) levels in HBV- producing cells. Knockdown of Atg7 or Atg13 suppressed hepatic autophagy, and it did not change SIRT1 protein, HBc protein or pgRNA levels in HBV- producing cells. Resveratrol, which increases SIRT1 expression and activity, promoted autophagy and increased HBc protein and pgRNA levels. siRNA-mediated knockdown of SIRT1 inhibited autophagy and decreased HBc protein and pgRNA levels. In SIRT1-knockdown cells, starvation promoted autophagy but did not increase HBc protein and pgRNA levels. In conclusion, HBc protein and pgRNA levels are upregulated not by the autophagic process itself but by the SIRT1 expression level.
  • Whole nucleocapsid protein of SARS-CoV-2 may cause false positive results in serological assays.
    Yutaro Yamaoka; Sundararaj S Jeremiah; Kei Miyakawa; Ryo Saji; Mototsugu Nishii; Ichiro Takeuchi; Akihide Ryo
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 72, 7, 1291, 1292, 2020年05月23日, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌)
  • Engineering Cellular Biosensors with Customizable Antiviral Responses Targeting Hepatitis B Virus.
    Satoko Matsunaga; Sundararaj S Jeremiah; Kei Miyakawa; Daisuke Kurotaki; Sayaka Shizukuishi; Koichi Watashi; Hironori Nishitsuji; Hirokazu Kimura; Tomohiko Tamura; Naoki Yamamoto; Kunitada Shimotohno; Takaji Wakita; Akihide Ryo
    iScience, 23, 3, 100867, 100867, 2020年03月27日, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌), SynNotch receptor technology is a versatile tool that uses the regulatory notch core portion with an extracellular scFv and an intracellular transcription factor that enables to program customized input and output functions in mammalian cells. In this study, we designed a novel synNotch receptor comprising scFv against HBs antigen linked with an intracellular artificial transcription factor and exploited it for viral sensing and cellular immunotherapy. The synNotch receptor expressing cells sensed HBV particles and membrane-bound HBs antigens and responded by expressing reporter molecules, secNL or GFP. We also programmed these cells to dispense antiviral responses such as type I interferon and anti-HBV neutralizing mouse-human chimeric antibodies. Our data reveal that synNotch receptor signaling works for membrane-bound ligands such as enveloped viral particles and proteins borne on liposomal vesicles. This study establishes the concepts of "engineered immunity" where the synNotch platform is utilized for cellular immunotherapy against viral infections.
  • Hepatitis C virus infection suppresses hepatitis B virus replication via the RIG-I-like helicase pathway.
    Kazuhiro Murai; Hayato Hikita; Yugo Kai; Yasuteru Kondo; Makoto Fukuoka; Keisuke Fukutomi; Akira Doi; Takuo Yamai; Tasuku Nakabori; Ryo Fukuda; Takeshi Takahashi; Kei Miyakawa; Hiroshi Suemizu; Akihide Ryo; Ryoko Yamada; Takahiro Kodama; Ryotaro Sakamori; Tomohide Tatsumi; Tetsuo Takehara
    Scientific reports, 10, 1, 941, 941, 2020年01月22日, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌), Mechanisms of hepatitis B virus (HBV) reactivation after hepatitis C virus (HCV) elimination by direct-acting antiviral (DAA) treatment in HBV/HCV-co-infected patients remain unclear. We examined RIG-I-like helicase (RLH) pathway activation by HBV mono-infection, HCV mono-infection or HBV/HCV co-infection and interference between HBV and HCV in primary human hepatocytes. Interference between HBV and HCV and HBV reactivation after DAA treatment in humanized-liver mice were assessed. HCV infection activated RLH pathway, as evidenced by RIG-I, ISG15 and ISG56 expression induction; HBV caused only RIG-I induction in vitro. RLH activation was also found in HBV/HCV-co-infected cells, and HBV replication were suppressed in HBV/HCV-co-infected than in HBV-mono-infected cells. siRNA-mediated double knockdown of ISG15 and ISG56 increased HBV replication in HBV/HCV-co-infected cells. HCV infection activated RLH pathway and suppressed HBV replication in humanized-liver mice. Subsequent elimination of HCV by DAA administration downregulated RLH pathway and upregulated HBV replication in mice. RLH pathway was activated in livers of chronic hepatitis C patients compared to those of chronic hepatitis B or non-B, non-C patients. The RLH pathway activation was downregulated by HCV elimination. In conclusion, HCV infection activated RLH pathway and suppressed HBV replication in human hepatocytes. HCV elimination upregulated HBV replication, probably through RLH pathway downregulation.
  • Development of an Automated Chemiluminescence Assay System for Quantitative Measurement of Multiple Anti-SARS-CoV-2 Antibodies.
    Sousuke Kubo; Norihisa Ohtake; Kei Miyakawa; Sundararaj Stanleyraj Jeremiah; Yutaro Yamaoka; Kota Murohashi; Eri Hagiwara; Takahiro Mihara; Atsushi Goto; Etsuko Yamazaki; Takashi Ogura; Takeshi Kaneko; Takeharu Yamanaka; Akihide Ryo
    Frontiers in microbiology, 11, 628281, 628281, 2020年, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌), Objectives: Serological tests for COVID-19 have been instrumental in studying the epidemiology of the disease. However, the performance of the currently available tests is plagued by the problem of variability. We have developed a high-throughput serological test capable of simultaneously detecting total immunoglobulins (Ig) and immunoglobulin G (IgG) against nucleocapsid protein (NP) and spike protein (SP) and report its performance in detecting COVID-19 in clinical samples. Methods: We designed and prepared reagents for measuring NP-IgG, NP-Total Ig, SP-IgG, and SP-Total Ig (using N-terminally truncated NP (ΔN-NP) or receptor-binding domain (RBD) antigen) dedicated automated chemiluminescent enzyme immunoassay analyzer AIA-CL1200. After determining the basal thresholds based on 17 sera obtained from confirmed COVID-19 patients and 600 negative sera, the clinical validity of the assay was evaluated using independent 202 positive samples and 1,000 negative samples from healthy donors. Results: All of the four test parameters showed 100% specificity individually (1,000/1,000; 95%CI, 99.63-100). The sensitivity of the assay increased proportionally to the elapsed time from symptoms onset, and all the tests achieved 100% sensitivity (153/153; 95%CI, 97.63-100) after 13 days from symptoms onset. NP-Total Ig was the earliest to attain maximal sensitivity among the other antibodies tested. Conclusion: Our newly developed serological testing exhibited 100% sensitivity and specificity after 13 days from symptoms onset. Hence, it could be used as a reliable method for accurate detection of COVID-19 patients and to evaluate seroprevalence and possibly for surrogate assessment of herd immunity.
  • Prolyl Isomerase Pin1 Regulates the Stability of Hepatitis B Virus Core Protein.
    Mayuko Nishi#; Kei Miyakawa#; Satoko Matsunaga; Hajera Khatun; Yutaro Yamaoka; Koichi Watashi; Masaya Sugiyama; Hirokazu Kimura; Takaji Wakita; Akihide Ryo
    Frontiers in cell and developmental biology, 8, 26, 26, 2020年, [査読有り], [筆頭著者], [国際誌]
    英語, 研究論文(学術雑誌), The dynamic interplay between virus and host proteins is critical for establishing efficient viral replication and virus-induced pathogenesis. Phosphorylation-dependent prolyl isomerization by Pin1 provides a unique mechanism of molecular switching to control both protein function and stability. We demonstrate here that Pin1 binds and stabilizes hepatitis B virus core protein (HBc) in a phosphorylation-dependent manner, and promotes the efficient viral propagation. Phos-tag gel electrophoresis with various site-directed mutants of HBc revealed that Thr160 and Ser162 residues within the C terminal arginine-rich domain are phosphorylated concomitantly. GST pull-down assay and co-immunoprecipitation analysis demonstrated that Pin1 associated with phosphorylated HBc at the Thr160-Pro and Ser162-Pro motifs. Chemical or genetic inhibition of Pin1 significantly accelerated the rapid degradation of HBc via a lysosome-dependent pathway. Furthermore, we found that the pyruvate dehydrogenase phosphatase catalytic subunit 2 (PDP2) could dephosphorylate HBc at the Pin1-binding sites, thereby suppressing Pin1-mediated HBc stabilization. Our findings reveal an important regulatory mechanism of HBc stability catalyzed by Pin1 and may facilitate the development of new antiviral therapeutics targeting Pin1 function.
  • Allosteric Regulation of HIV-1 Capsid Structure for Gag Assembly, Virion Production, and Viral Infectivity by a Disordered Interdomain Linker.
    Takaaki Koma; Osamu Kotani; Kei Miyakawa; Akihide Ryo; Masaru Yokoyama; Naoya Doi; Akio Adachi; Hironori Sato; Masako Nomaguchi
    Journal of virology, 93, 17, 2019年09月01日, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌), The retroviral Gag capsid (Gag-CA) interdomain linker is an unstructured peptide segment connecting structured N-terminal and C-terminal domains. Although the region is reported to play roles in virion morphogenesis and infectivity, underlying molecular mechanisms remain unexplored. To address this issue, we determined biological and molecular phenotypes of HIV-1 CA linker mutants by experimental and in silico approaches. Among the nine linker mutants tested, eight exhibited attenuation of viral particle production to various extents mostly in parallel with a reduction in viral infectivity. Sucrose density gradient, confocal microscopy, and live-cell protein interaction analyses indicated that the defect is accompanied by attenuation of Gag-Gag interactions following Gag plasma membrane targeting in the cells. In silico analyses revealed distinct distributions of interaction-prone hydrophobic patches between immature and mature CA proteins. Molecular dynamics simulations predicted that the linker mutations can allosterically alter structural fluctuations, including the interaction surfaces apart from the mutation sites in both the immature and mature CA proteins. These results suggest that the HIV-1 CA interdomain linker is a cis-modulator of the CA interaction surfaces to optimize efficiency of Gag assembly, virion production, and viral infectivity.IMPORTANCE HIV-1 particle production and infection are highly ordered processes. Viral Gag proteins play a central role in the assembly and disassembly of viral molecules. Of these, capsid protein (CA) is a major contributor to the Gag-Gag interactions. CA consists of two structured domains, i.e., N-terminal (NTD) and C-terminal (CTD) domains, connected by an unstructured domain named the interdomain linker. While multiple regions in the NTD and CTD are reported to play roles in virion morphogenesis and infectivity, the roles of the linker region in Gag assembly and virus particle formation remain elusive. In this study, we showed by biological and molecular analyses that the linker region functions as an intramolecular modulator to tune Gag assembly, virion production, and viral infectivity. Our study thus illustrates a hitherto-unrecognized mechanism, an allosteric regulation of CA structure by the disordered protein element, for HIV-1 replication.
  • PIM kinases facilitate lentiviral evasion from SAMHD1 restriction via Vpx phosphorylation.
    Kei Miyakawa; Satoko Matsunaga; Masaru Yokoyama; Masako Nomaguchi; Yayoi Kimura; Mayuko Nishi; Hirokazu Kimura; Hironori Sato; Hisashi Hirano; Tomohiko Tamura; Hirofumi Akari; Tomoyuki Miura; Akio Adachi; Tatsuya Sawasaki; Naoki Yamamoto; Akihide Ryo
    Nature communications, 10, 1, 1844, 1844, 2019年04月23日, [査読有り], [筆頭著者], [国際誌]
    英語, 研究論文(学術雑誌), Lentiviruses have evolved to acquire an auxiliary protein Vpx to counteract the intrinsic host restriction factor SAMHD1. Although Vpx is phosphorylated, it remains unclear whether such phosphorylation indeed regulates its activity toward SAMHD1. Here we identify the PIM family of serine/threonine protein kinases as the factors responsible for the phosphorylation of Vpx and the promotion of Vpx-mediated SAMHD1 counteraction. Integrated proteomics and subsequent functional analysis reveal that PIM family kinases, PIM1 and PIM3, phosphorylate HIV-2 Vpx at Ser13 and stabilize the interaction of Vpx with SAMHD1 thereby promoting ubiquitin-mediated proteolysis of SAMHD1. Inhibition of the PIM kinases promotes the antiviral activity of SAMHD1, ultimately reducing viral replication. Our results highlight a new mode of virus-host cell interaction in which host PIM kinases facilitate promotion of viral infectivity by counteracting the host antiviral system, and suggest a novel therapeutic strategy involving restoration of SAMHD1-mediated antiviral response.
  • Recapitulation of hepatitis B virus-host interactions in liver organoids from human induced pluripotent stem cells.
    Yun-Zhong Nie; Yun-Wen Zheng; Kei Miyakawa; Soichiro Murata; Ran-Ran Zhang; Keisuke Sekine; Yasuharu Ueno; Takanori Takebe; Takaji Wakita; Akihide Ryo; Hideki Taniguchi
    EBioMedicine, 35, 114, 123, 2018年09月, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌), Therapies against hepatitis B virus (HBV) have improved in recent decades; however, the development of individualized treatments has been limited by the lack of individualized infection models. In this study, we used human induced pluripotent stem cell (hiPSC) to generate a functional liver organoid (LO) that inherited the genetic background of the donor, and evaluated its application in modeling HBV infection and exploring virus-host interactions. To establish a functional hiPSC-LO, we cultured hiPSC-derived endodermal, mesenchymal, and endothelial cells with a chemically defined medium in a three-dimensional microwell culture system. Based on cell-cell interactions, these cells could organize themselves and gradually differentiate into a functional organoid, which exhibited stronger hepatic functions than hiPSC derived hepatic like cell (HLC). Moreover, the functional LO demonstrated more susceptibility to HBV infection than hiPSC-HLC, and could maintain HBV propagation and produce infectious virus for a prolonged duration. Furthermore, we found that virus infection could cause hepatic dysfunction of hiPSC-LOs, with down-regulation of hepatic gene expression, induced release of early acute liver failure markers, and altered hepatic ultrastructure. Therefore, our study demonstrated that HBV infection in hiPSC-LOs could recapitulate virus life cycle and virus induced hepatic dysfunction, suggesting that hiPSC-LOs may provide a promising individualized infection model for the development of individualized treatment for hepatitis.
  • Development of a cell-based assay to identify hepatitis B virus entry inhibitors targeting the sodium taurocholate cotransporting polypeptide.
    Kei Miyakawa; Satoko Matsunaga; Yutaro Yamaoka; Mina Dairaku; Kento Fukano; Hirokazu Kimura; Tomoyuki Chimuro; Hironori Nishitsuji; Koichi Watashi; Kunitada Shimotohno; Takaji Wakita; Akihide Ryo
    Oncotarget, 9, 34, 23681, 23694, 2018年05月04日, [査読有り], [筆頭著者], [国際誌]
    英語, 研究論文(学術雑誌), Sodium taurocholate cotransporting polypeptide (NTCP) is a major entry receptor of hepatitis B virus (HBV) and one of the most attractive targets for anti-HBV drugs. We developed a cell-mediated drug screening method to monitor NTCP expression on the cell surface by generating a HepG2 cell line with tetracycline-inducible expression of NTCP and a monoclonal antibody that specifically detects cell-surface NTCP. Using this system, we screened a small molecule library for compounds that protected against HBV infection by targeting NTCP. We found that glabridin, a licorice-derived isoflavane, could suppress viral infection by inducing caveolar endocytosis of cell-surface NTCP with an IC50 of ~40 μM. We also found that glabridin could attenuate the inhibitory effect of taurocholate on type I interferon signaling by depleting the level of cell-surface NTCP. These results demonstrate that our screening system could be a powerful tool for discovering drugs targeting HBV entry.
  • がん抑制遺伝子産物APCはHIV細胞-細胞間感染を促進する
    宮川 敬; 梁 明秀
    感染・炎症・免疫, 47, 4, 302, 304, 2017年12月
  • The tumour suppressor APC promotes HIV-1 assembly via interaction with Gag precursor protein
    Kei Miyakawa; Mayuko Nishi; Satoko Matsunaga; Akiko Okayama; Masaki Anraku; Ayumi Kudoh; Hisashi Hirano; Hirokazu Kimura; Yuko Morikawa; Naoki Yamamoto; Akira Ono; Akihide Ryo
    Nature Communications, 8, 14259, 2017年01月, [査読有り], [筆頭著者]
    英語, 研究論文(学術雑誌)
  • H11/HSPB8 Restricts HIV-2 Vpx to Restore the Anti-Viral Activity of SAMHD1
    Ayumi Kudoh; Kei Miyakawal; Satoko Matsunagal; Yuki Matsushima; Isao Kosugi; Hirokazu Kimura; Satoshi Hayakawa; Tatsuya Sawasaki; Akihide Ryo
    FRONTIERS IN MICROBIOLOGY, 7, 883, 2016年06月, [査読有り]
    英語, 研究論文(学術雑誌)
  • Cooperative Orthogonal Macromolecular Assemblies with Broad Spectrum Antiviral Activity, High Selectivity, and Resistance Mitigation
    Koji Ichiyama; Chuan Yang; Lakshmi Chandrasekaran; Shaoqiong Liu; Lijun Rong; Yue Zhao; Shujun Gao; Ashlynn Lee; Kenji Ohba; Youichi Suzuki; Yoshiyuki Yoshinaka; Kunitada Shimotohno; Kei Miyakawa; Akihide Ryo; James Hedrick; Naoki Yamamoto; Yi Yan Yang
    MACROMOLECULES, 49, 7, 2618, 2629, 2016年04月, [査読有り]
    英語, 研究論文(学術雑誌)
  • Molecular dissection of HBV evasion from restriction factor tetherin: A new perspective for antiviral cell therapy
    Kei Miyakawa; Satoko Matsunaga; Koichi Watashi; Masaya Sugiyama; Hirokazu Kimura; Naoki Yamamoto; Masashi Mizokami; Takaji Wakita; Akihide Ryo
    Oncotarget, 6, 26, 21840, 21852, 2015年09月, [査読有り], [筆頭著者]
    英語, 研究論文(学術雑誌)
  • ASK1 restores the antiviral activity of APOBEC3G by disrupting HIV-1 Vif-mediated counteraction
    Kei Miyakawa; Satoko Matsunaga; Kazuhiko Kanou; Atsushi Matsuzawa; Ryo Morishita; Ayumi Kudoh; Keisuke Shindo; Masaru Yokoyama; Hironori Sato; Hirokazu Kimura; Tomohiko Tamura; Naoki Yamamoto; Hidenori Ichijo; Akifumi Takaori-Kondo; Akihide Ryo
    Nature Communications, 6, 6945, 2015年04月, [査読有り], [筆頭著者]
    英語, 研究論文(学術雑誌)
  • The phosphorylation of HIV-1 Gag by atypical protein kinase C facilitates viral infectivity by promoting Vpr incorporation into virions
    Ayumi Kudoh; Shoukichi Takahama; Tatsuya Sawasaki; Hirotaka Ode; Masaru Yokoyama; Akiko Okayama; Akiyo Ishikawa; Kei Miyakawa; Satoko Matsunaga; Hirokazu Kimura; Wataru Sugiura; Hironori Sato; Hisashi Hirano; Shigeo Ohno; Naoki Yamamoto; Akihide Ryo
    RETROVIROLOGY, 11, 9, 2014年01月, [査読有り]
    英語, 研究論文(学術雑誌)
  • Generation of rhesus macaque-tropic HIV-1 clones that are resistant to major anti-HIV-1 restriction factors.
    Masako Nomaguchi; Masaru Yokoyama; Ken Kono; Emi E Nakayama; Tatsuo Shioda; Naoya Doi; Sachi Fujiwara; Akatsuki Saito; Hirofumi Akari; Kei Miyakawa; Akihide Ryo; Hirotaka Ode; Yasumasa Iwatani; Tomoyuki Miura; Tatsuhiko Igarashi; Hironori Sato; Akio Adachi
    Journal of virology, 87, 21, 11447, 61, 2013年11月, [査読有り], [国際誌]
    英語, Human immunodeficiency virus type 1 (HIV-1) replication in macaque cells is restricted mainly by antiviral cellular APOBEC3, TRIM5α/TRIM5CypA, and tetherin proteins. For basic and clinical HIV-1/AIDS studies, efforts to construct macaque-tropic HIV-1 (HIV-1mt) have been made by us and others. Although rhesus macaques are commonly and successfully used as infection models, no HIV-1 derivatives suitable for in vivo rhesus research are available to date. In this study, to obtain novel HIV-1mt clones that are resistant to major restriction factors, we altered Gag and Vpu of our best HIV-1mt clone described previously. First, by sequence- and structure-guided mutagenesis, three amino acid residues in Gag-capsid (CA) (M94L/R98S/G114Q) were found to be responsible for viral growth enhancement in a macaque cell line. Results of in vitro TRIM5α susceptibility testing of HIV-1mt carrying these substitutions correlated well with the increased viral replication potential in macaque peripheral blood mononuclear cells (PBMCs) with different TRIM5 alleles, suggesting that the three amino acids in HIV-1mt CA are involved in the interaction with TRIM5α. Second, we replaced the transmembrane domain of Vpu of this clone with the corresponding region of simian immunodeficiency virus SIVgsn166 Vpu. The resultant clone, MN4/LSDQgtu, was able to antagonize macaque but not human tetherin, and its Vpu effectively functioned during viral replication in a macaque cell line. Notably, MN4/LSDQgtu grew comparably to SIVmac239 and much better than any of our other HIV-1mt clones in rhesus macaque PBMCs. In sum, MN4/LSDQgtu is the first HIV-1 derivative that exhibits resistance to the major restriction factors in rhesus macaque cells.
  • Interferon-induced SCYL2 limits release of HIV-1 by triggering PP2A-mediated dephosphorylation of the viral protein Vpu.
    Kei Miyakawa; Tatsuya Sawasaki; Satoko Matsunaga; Andrey Tokarev; Gary Quinn; Hirokazu Kimura; Masako Nomaguchi; Akio Adachi; Naoki Yamamoto; John Guatelli; Akihide Ryo
    Science signaling, 5, 245, ra73, 2012年10月09日, [査読有り], [筆頭著者], [国際誌]
    英語, Human cells respond to infection by retroviruses through the actions of proteins that inhibit the spread of viruses to other cells. One example is bone marrow stromal cell antigen 2 (BST2; also known as tetherin), which is an interferon (IFN)-inducible protein that restricts the release of progeny virions from infected cells. The HIV-1 accessory protein Vpu (viral protein U) causes degradation of BST2, and phosphorylation of Vpu at residues Ser(52) and Ser(56) is required for this function. We report that the host protein SCY1-like protein 2 (SCYL2) mediates the dephosphorylation of Vpu, antagonizing Vpu function and facilitating BST2-dependent restriction of HIV-1 release. SCYL2 reduced the number of virus particles released from cells infected with wild-type HIV-1, but not a strain lacking vpu, in a BST2-dependent manner. SCYL2 stimulated the dephosphorylation of Vpu on Ser(52) and Ser(56) by recruiting protein phosphatase 2A (PP2A) to Vpu. Conversely, depletion of SCYL2 resulted in enhanced phosphorylation of Vpu and increased viral particle release. Moreover, SCYL2 was produced in response to type I IFN and contributed to IFN-mediated viral restriction. Together, these results suggest that SCYL2 serves as a regulatory factor for Vpu, reducing the extent of Vpu phosphorylation and consequently enhancing BST2-mediated viral restriction.
  • 宿主防御因子Tetherinとウイルスの攻防
    宮川 敬; 梁 明秀
    日本エイズ学会誌, 14, 1, 17, 24, 日本エイズ学会, 2012年01月
    日本語
  • HIV感染と宿主因子-エイズ制圧にむけて
    梁 明秀; 宮川 敬
    横浜医学, 62, 1・2, 35, 41, 横浜市立大学医学会, 2011年03月, [査読有り]
    日本語
  • BCA2/Rabring7 Promotes Tetherin-Dependent HIV-1 Restriction
    Kei Miyakawa; Akihide Ryo; Tsutomu Murakami; Kenji Ohba; Shoji Yamaoka; Mitsunori Fukuda; John Guatelli; Naoki Yamamoto
    PLOS PATHOGENS, 5, 12, e1000700, 2009年12月, [査読有り], [筆頭著者]
    英語, 研究論文(学術雑誌)
  • Effects of the ligand sequence modifications on the retargeted transduction by the retroviral vector having a ligand-chimeric Env protein
    Kei Miyakawa; Rika Fujita; Masuni Katane; Yoshinao Kubo; Hiroshi Amanuma
    JOURNAL OF GENERAL VIROLOGY, 89, Pt 12, 3137, 3143, 2008年12月, [査読有り]
    英語, 研究論文(学術雑誌)
■ その他活動・業績
  • 紙・電界紡糸ファイバー二層基材で作製した呼吸器組織モデルでのウイルス感染防御評価
    伊藤 彩夏; 田中 諒; 井本 菜月; 新井 啓太; 土戸 優志; 宮川 敬; 武田 直也, 日本バイオマテリアル学会大会予稿集, 47回, 3D, 1, 2025年11月
    日本バイオマテリアル学会, 日本語
  • Long COVIDにおけるS-IgG4クラススイッチングと症状改善の関連性
    宮川 敬; 佐野 芳; 木村 弥生; 平畑 光一; 加藤 英明; 長谷川 秀樹; 梁 明秀; 後藤 温, 臨床とウイルス, 53, 3, 189, 189, 2025年09月
    日本臨床ウイルス学会, 日本語
  • SARS-CoV-2 mRNAワクチンの頻回接種によるIgGサブクラス動態 初期変化とその長期安定性
    佐野 芳; 加藤 英明; 梁 明秀; 長谷川 秀樹; 宮川 敬, 臨床とウイルス, 53, 3, 234, 234, 2025年09月
    日本臨床ウイルス学会, 日本語
  • 発光性ウイルス様粒子を用いた高病原性鳥インフルエンザ中和抗体の迅速評価系の開発
    太田 真; 佐野 芳; 百瀬 文隆; 岸田 典子; 有田 知子; 鈴木 康司; 白倉 雅之; 浅沼 秀樹; 渡邉 真治; 長谷川 秀樹; 宮川 敬, 臨床とウイルス, 53, 3, 237, 237, 2025年09月
    日本臨床ウイルス学会, 日本語
  • 新型コロナワクチンの接種前後の抗体価および中和抗体活性の検討-mRNAワクチンと組換えタンパクワクチンの比較検討-
    佐藤諒一; 関洋平; 佐々木恭平; 荒井仁美; 高島瑶子; 中村賢; 小林喜臣; 谷戸祥之; 杉山学子; 野島清子; 櫻木小百合; 宮川敬; 宮崎かや; 松山州徳; 長谷川秀樹; 水上拓郎; 吉原愛雄, 国立病院総合医学会(Web), 79th, 2025年
  • 質量分析計を用いた病院排水メタプロテオームモニタリング
    堀川和男; 宮川敬; SHIN Jihye; 松永展明; 黒田誠; 梁明秀; 木村弥生, 日本プロテオーム学会大会プログラム・抄録集, 2025, 2025年
  • Phos-tag Click Tipを用いた新規合成タンパク質選択的濃縮法の開発
    秋山知子; 小橋達弘; 細谷麻以子; 井野洋子; SHIN Jihye; 宮川敬; 木下英司; 梁明秀, 日本プロテオーム学会大会プログラム・抄録集, 2025, 2025年
  • Phos-tag Click Tip法を用いた高感度新規合成タンパク質プロファイリング
    細谷麻以子; 秋山知子; 宮川敬; 小橋達弘; 井野洋子; SHIN Jihye; 木下英司; 梁明秀; 木村弥生, 日本プロテオーム学会大会プログラム・抄録集, 2025, 2025年
  • 紙を基盤とした二層基材を用いたウイルス感染を評価する呼吸器組織モデルの作製
    伊藤彩夏; 田中諒; 井本菜月; 新井啓太; 土戸優志; 宮川敬; 武田直也, セルロース学会年次大会講演要旨集, 32nd, 2025年
  • 日本人医療従事者におけるOmicron XBB.1.5ワクチン接種後の免疫応答の解析
    佐野 芳; 加藤 英明; 長谷川 秀樹; 宮川 敬, 臨床とウイルス, 52, 3, 172, 172, 2024年10月
    日本臨床ウイルス学会, 日本語
  • 新型コロナウイルスワクチン接種における免疫への影響について
    藤本 友香; 梁 明秀; 宮川 敬; 浅見 知市郎; 林 由里子; 白井 達也; 佐田 充; 長田 誠; 亀子 光明; 木村 博一, 日本未病学会雑誌, 30, 1, 27, 30, 2024年03月
    (一社)日本未病学会, 日本語
  • ボカウイルスの検出に適したモノクローナル抗体の開発
    亀谷太一; 亀谷太一; 亀谷太一; 柿崎正敏; 巳鼻佑作; 巳鼻佑作; 巳鼻佑作; 山岡悠太郎; 山岡悠太郎; 山岡悠太郎; 澤口智哉; 宮川敬; 宮川敬; 白戸憲也; 梁明秀; 梁明秀, 日本ウイルス学会学術集会プログラム・予稿集(Web), 71st, 2024年
  • SARS-CoV-2ORF8はKeap1-Nrf2制御系による抗酸化応答を誘導する
    大倉喬; 西嶋陽奈; 亀谷太一; 亀谷太一; 畑山靖佳; 柿崎正敏; 宮川敬; 白戸憲也; 梁明秀, 日本ウイルス学会学術集会プログラム・予稿集(Web), 71st, 2024年
  • ヒトプロテインビーズアレイを活用したLong COVIDの病態に関与する自己抗体の探索
    畑山靖佳; 堀川和男; 宮川敬; 平畑光一; 加藤英明; 木村弥生; 後藤温; 梁明秀, 日本ウイルス学会学術集会プログラム・予稿集(Web), 71st, 2024年
  • PITの現状と展望 光免疫療法を応用した標的選択的な病原体除去法photoimmuno-antimictobial strategyの開発
    光永 眞人; 西村 尚; 伊藤 公博; 宮川 敬; 梁 明秀; 小林 久隆; 岩瀬 忠行, 日本レーザー医学会誌, 44, 3, 304, 304, 2023年09月
    (NPO)日本レーザー医学会, 日本語
  • 新型コロナウイルスワクチン接種による発熱の有無が中和抗体価に及ぼす影響
    藤本 友香; 梁 明秀; 宮川 敬; 浅見 知市郎; 林 由里子; 亀子 光明; 小河原 はつ江; 木村 博一, 日本医学検査学会抄録集, 72回, 447, 447, 2023年05月
    (一社)日本臨床衛生検査技師会, 日本語
  • Proximity-dependent biotin identification法を用いたA型インフルエンザウイルスNS1タンパク質と相互作用する宿主因子の同定とウイルス複製における機能解析
    中内美名; 井野洋子; 高橋仁; 信澤枝里; 宮川敬; 木村弥生; 梁明秀; 長谷川秀樹, 日本ウイルス学会学術集会プログラム・予稿集(Web), 70th, 2023年
  • SARS-CoV-2アクセサリータンパク質ORF8の発現量を制御する宿主因子の探索
    西嶋陽奈; 宮川敬; 原田勇一; 梁明秀, 日本ウイルス学会学術集会プログラム・予稿集(Web), 70th, 2023年
  • 腸管オルガノイドを用いたSARS-CoV-2性状解析
    宮川敬; 阿久津英憲; 長谷川秀樹; 梁明秀, 日本ウイルス学会学術集会プログラム・予稿集(Web), 70th, 2023年
  • 新型コロナウイルスワクチン接種における免疫への影響について
    藤本 友香; 梁 明秀; 宮川 敬; 浅見 知市郎; 林 由里子; 白井 達也; 佐田 充; 長田 誠; 亀子 光明; 木村 博一; 小河原 はつ江, 日本未病学会学術総会抄録集, 29, 98, 98, 2022年10月
    (一社)日本未病学会, 日本語
  • Phos-tag技術を用いた新型コロナウイルスヌクレオカプシドタンパク質(NP)の機能的リン酸化部位の同定
    井野洋子; 西真由子; 山岡悠太郎; 山岡悠太郎; 宮川敬; 梁明秀; 梁明秀; 木村弥生, 日本プロテオーム学会大会プログラム・抄録集, 255, 104501, 104501, 2022年03月20日, [国際誌]
    Phosphorylation of viral proteins serves as a regulatory mechanism during the intracellular life cycle of infected viruses. There is therefore a pressing need to develop a method to efficiently purify and enrich phosphopeptides derived from viral particles in biological samples. In this study, we utilized Phos-tag technology to analyze the functional phosphorylation of the nucleocapsid protein (N protein; NP) of severe respiratory syndrome coronavirus 2 (SARS-CoV-2). Viral particles were collected from culture supernatants of SARS-CoV-2-infected VeroE6/TMPRSS2 cells by ultracentrifugation, and phosphopeptides were purified by Phos-tag magnetic beads for LC-MS/MS analysis. Analysis revealed that NP was reproducibly phosphorylated at serine 79 (Ser79). Multiple sequence alignment and phylogenetic analysis showed that the Ser79 was a distinct phospho-acceptor site in SARS-CoV-2 but not in other beta-coronaviruses. We also found that the prolyl-isomerase Pin1 bound to the phosphorylated Ser79 in NP and positively regulated the production of viral particles. These results suggest that SARS-CoV-2 may have acquired the potent virus-host interaction during its evolution mediated by viral protein phosphorylation. Moreover, Phos-tag technology can provide a useful means for analyzing the functional phosphorylation of viral proteins. SIGNIFICANCE: In this study, we aimed to investigate the functional phosphorylation of SARS-CoV-2 NP. For this purpose, we used Phos-tag technology to purify and enrich virus-derived phosphopeptides with high selectivity and reproducibility. This method can be particularly useful in analyzing viral phosphopeptides from cell culture supernatants that often contain high concentrations of fetal bovine serum and supplements. We newly identified an NP phosphorylation site at Ser79, which is important for Pin1 binding. Furthermore, we showed that the interaction between Pin1 and phosphorylated NP could enhance viral replication in a cell culture model., 英語
  • AlphaScreenを用いたハイスループットなSARS-CoV-2 3CLpro活性評価系の構築と阻害化合物の探索
    森田 武志; 宮川 敬; 國吉 智子; 楊 金緯; 梁 明秀, 日本薬学会年会要旨集, 142年会, 26M, pm21S, 2022年03月
    (公社)日本薬学会, 日本語
  • COVID-19に対する新しい検査法の開発
    宮川敬; 梁明秀, 日本薬学会関東支部大会講演要旨集, 66th (CD-ROM), 2022年
  • 新型コロナウイルス感染症に対する新たな検査法の開発と実用化
    梁明秀; 宮川敬, 日本エイズ学会誌, 23, 4, 2021年11月
  • ウイルス-宿主タンパク質相互作用解析とその応用
    宮川敬; 梁明秀, 日本エイズ学会誌, 23, 4, 2021年11月
  • SARS-CoV-2ヌクレオカプシドタンパク質のリン酸化のおよびプロリン異性化酵素Pin1との相互作用解析
    井野 洋子; 西 真由子; 山岡 悠太郎; 宮川 敬; 木村 弥生; 梁 明秀, 電気泳動, 65, Suppl., s24, s24, 2021年07月
    日本電気泳動学会, 日本語
  • In situビオチン化法を用いたB型肝炎ウイルスのコアタンパク質と相互作用する宿主因子群の探索
    中居 佑介; 宮川 敬; 山岡 悠太郎; 鈴木 秀文; 高橋 秀尚; 木村 弥生; 梁 明秀, 電気泳動, 65, Suppl., s49, s49, 2021年07月
    日本電気泳動学会, 日本語
  • アルファスクリーンを用いた血清中の抗HTLV-1抗体測定法の開発
    舩橋 利佳子; 鈴木 智津; 山岡 悠太郎; 宮川 敬; 木村 弥生; 梁 明秀, 電気泳動, 65, Suppl., s57, s57, 2021年07月
    日本電気泳動学会, 日本語
  • SARS-CoV-2ヌクレオカプシドタンパク質のリン酸化のおよびプロリン異性化酵素Pin1との相互作用解析
    井野 洋子; 西 真由子; 山岡 悠太郎; 宮川 敬; 木村 弥生; 梁 明秀, 電気泳動, 65, Suppl., s24, s24, 2021年07月
    日本電気泳動学会, 日本語
  • In situビオチン化法を用いたB型肝炎ウイルスのコアタンパク質と相互作用する宿主因子群の探索
    中居 佑介; 宮川 敬; 山岡 悠太郎; 鈴木 秀文; 高橋 秀尚; 木村 弥生; 梁 明秀, 電気泳動, 65, Suppl., s49, s49, 2021年07月
    日本電気泳動学会, 日本語
  • アルファスクリーンを用いた血清中の抗HTLV-1抗体測定法の開発
    舩橋 利佳子; 鈴木 智津; 山岡 悠太郎; 宮川 敬; 木村 弥生; 梁 明秀, 電気泳動, 65, Suppl., s57, s57, 2021年07月
    日本電気泳動学会, 日本語
  • HIV-1カプシド“disorder”領域の構造機能解析
    小谷治; 駒貴明; 宮川敬; 梁明秀; 横山勝; 土肥直哉; 足立昭夫; 野間口雅子; 佐藤裕徳, 日本エイズ学会誌, 21, 4, 2019年
  • ピックアップ演題によるワークショップ NanoBRET法を用いた生細胞内HIV-1 Gagの多量体化解析および結合宿主因子探索
    宮川 敬; 松山 慎一郎; 村上 努; 梁 明秀, 日本エイズ学会誌, 18, 4, 393, 393, 2016年11月
    (一社)日本エイズ学会, 日本語
  • ケミカルバイオロジーを用いたHIV再活性化のメカニズム解析
    岩瀬 早織; 宮川 敬; 工藤 あゆみ; 梁 明秀, 日本エイズ学会誌, 18, 4, 490, 490, 2016年11月
    (一社)日本エイズ学会, 日本語
  • APOBEC3Gのアセチル化修飾と機能調節
    福田寛文; 松井佑亮; 白川康太郎; 和田典也; 宮川敬; 梁明秀; 高折晃史, 日本エイズ学会誌, 17, 4, 374, 374, 2015年11月20日
    (一社)日本エイズ学会, 日本語
  • 微生物学をリードするBasic Retrovirology 癌抑制遺伝子産物APCによるHIV Gag前駆体/vRNA輸送機構の解析
    宮川 敬; 西 真由子; 松永 智子; 岡山 明子; 森川 裕子; 平野 久; 山本 直樹; 小野 陽; 梁 明秀, 日本エイズ学会誌, 17, 4, 332, 332, 2015年11月
    (一社)日本エイズ学会, 日本語
  • HIV-1 Vpuの翻訳後修飾とその意義
    佐藤 遥; 宮川 敬; 工藤 あゆみ; 梁 明秀, 日本エイズ学会誌, 14, 4, 332, 332, 2012年11月
    (一社)日本エイズ学会, 日本語
  • HIVの構造基本情報と制御 HIV-1 Vif-APOBEC3Gの相互作用を調節する新規宿主因子の同定
    宮川 敬; 森下 了; 道場 生基; 松永 智子; 工藤 あゆみ; 高折 晃史; 梁 明秀, 日本エイズ学会誌, 14, 4, 301, 301, 2012年11月
    (一社)日本エイズ学会, 日本語
  • HIVアクセサリー蛋白質Vpxと相互作用する宿主因子の網羅的探索と機能解析
    工藤あゆみ; 宮川敬; 松永智子; 森下了; 早川智; 梁明秀, 日本エイズ学会誌, 14, 4, 2012年
  • 感染機構とその制御 生得性抗ウイルス反応におけるHIV-1 Vpuの翻訳後修飾(Posttranslational modification of HIV-1 Vpu in an innate antiviral response)
    宮川 敬; 澤崎 達也; 松永 智子; 山本 直樹; 梁 明秀, 日本エイズ学会誌, 13, 4, 330, 330, 2011年11月
    (一社)日本エイズ学会, 英語
  • A New Host Restriction Factor Promoting HIV-1 Particle Destruction
    Kei Miyakawa; Akihide Ryo, EUROPEAN JOURNAL OF MEDICAL RESEARCH, 15, 8, 330, 330, 2010年08月
    英語, 研究発表ペーパー・要旨(国際会議)
  • 宿主蛋白質BCA2/Rabring7はTetherinと協調してHIV-1粒子産生を抑制する
    宮川 敬; 梁 明秀, 横浜医学, 61, 2, 157, 158, 2010年03月
    横浜市立大学医学会, 日本語
  • RINGフィンガー蛋白質BCA2はHIV-1粒子産生を阻害する
    宮川敬; 梁明秀; 大庭賢二; 村上努; 山本直樹, 日本エイズ学会誌, 10, 4, 2008年
  • マウスレトロウイルス Env 蛋白質の受容体特異性の改変
    天沼 宏; 藤田 利香; 片根 真澄; 宮川 敬, 薬学雑誌, 124, Suppl. 4, 161, 164, 2004年
    英語
■ 所属学協会
  • 日本エイズ学会
  • 日本ウイルス学会
  • 日本ワクチン学会
■ 共同研究・競争的資金等の研究課題
  • sIgA 産生機構解明に基づく経鼻ワクチン高効率化技術の開発
    新興・再興感染症研究基盤創生事業(多分野融合研究領域)
    2025年09月 - 2028年03月
    研究代表者
    日本医療研究開発機構, 研究代表者
  • 細胞内外の環境変化によるウイルス感染制御機構の解明
    科学研究費助成事業
    2023年04月 - 2026年03月
    研究代表者
    効果的なワクチンや治療薬が存在しないウイルス感染症に対しては、ウイルスの複製機序や病原性発現機構を理解し、治療標的を特定する基礎研究が重要である。本研究では、ヒトが本来有する内因性免疫による宿主防御メカニズムを詳細に紐解くことで、ウイルス感染症に対する予防戦略の確立を目指す。本年度は、新型コロナウイルス感染症の原因ウイルスであるSARS-CoV-2に対する、未知の宿主防御メカニズムの解明を目指した。SARS-CoV-2は呼吸器以外の臓器にも感染し、多岐にわたる影響を及ぼすことが知られている。そこで我々は、さまざまな臓器由来の細胞・オルガノイドに、SARS-CoV-2デルタ株、オミクロン株(BA.1, BA.2, BA.2.75, BA.5, XBB.1系統)を感染させたところ、肺由来の細胞においては、デルタ株、オミクロン株ともに増殖効率が高かった。一方、ヒト腸管オルガノイドにおいては、デルタ株と一部のオミクロン株(BA.2.75系統)は高い増殖効率を示したのの、その他のオミクロン株は感染はするがほとんど増殖しないことを見出した。また、SARS-CoV-2感染腸管オルガノイドからは多様なサイトカインが分泌されており、とくにインターロイキン6の分泌量はウイルスの増殖効率と相関し、腸管への感染に伴う顕著な炎症反応が示唆された。反対に、インターフェロンラムダ2(IFN-λ2)の分泌量はウイルスの増殖効率と逆相関することが分かった。デルタ株の感染時にIFN-λ2を添加すると、ウイルス増殖が顕著に抑制された。また、IFN-λ2中和抗体をBA.2感染時に添加するとウイルス増殖が亢進した。これらの結果から、IFN-λ2は腸における内因性免疫の働きを高め、SARS-CoV-2感染抑制に重要な役割を果たすことが示唆された。
    日本学術振興会, 基盤研究(B), 国立感染症研究所, 研究代表者, 23K27419
  • ウイルス抗原特異的IgG4に着目したLong COVID症状改善メカニズムの解明
    内藤記念科学奨励金・研究助成
    2025年
    研究代表者
    研究代表者
  • 腸管オルガノイドを用いたCOVID-19罹患後症状に対する予防法開発
    新興・再興感染症に対する革新的医薬品等開発推進研究事業
    2023年04月 - 2024年03月
    研究代表者
    日本医療研究開発機構, 研究代表者
  • 腸管オルガノイドを用いたIFN-λ2誘導性SARS-CoV-2感染抑制機構の解明
    2024年
    研究代表者
    持田記念医学薬学振興財団研究助成, 研究代表者
  • HIV構造蛋白質Gagの機能制御機構の解析
    科学研究費助成事業
    2019年04月 - 2022年03月
    研究代表者
    HIV構造タンパク質Gagは、ウイルス複製に関わる重要因子であるにも関わらず、宿主免疫による制御機構は不明である。本研究では、自然免疫関連因子のうちGagの機能制御に関わる因子を包括的に探索、解析した。その結果、膜貫通型タンパク質MALがGagと強く相互作用する宿主タンパク質として同定された。MAL発現細胞では、HIV粒子産生が顕著に抑制され、その細胞内のエンドソームにGagが蓄積していた。しかし、MALの抗ウイルス活性は、HIVアクセサリータンパク質Nefによって阻害された。これらの結果から、ヒトが本来有する抗ウイルス活性がウイルスによって不活化される新たな機構が明らかとなった。
    日本学術振興会, 基盤研究(C), 横浜市立大学, 研究代表者, 19K07594
  • B型肝炎ウイルスの細胞侵入を標的とするモダリティの創出
    2022年
    研究代表者
    武田科学振興財団 医学系研究助成, 研究代表者
  • ウイルス感染伝播の時空間的解析法の開発
    エイズ対策実用化研究事業
    2018年04月 - 2021年03月
    研究代表者
    日本医療研究開発機構, 研究代表者, 競争的資金
  • 微小環境の変化によるHIV潜伏化機構の解明
    科学研究費補助金
    2016年04月 - 2019年03月
    研究代表者
    文部科学省, 基盤研究(C), 研究代表者, 競争的資金
  • HIV潜伏・再活性化メカニズムの解明
    2019年
    研究代表者
    今井保太郎記念エイズ研究助成, 研究代表者
  • HIV潜伏感染に関わる宿主因子の探索と機能解析
    2017年
    研究代表者
    横浜総合医学振興財団推進研究助成, 研究代表者
  • B型肝炎ウイルス感染に対する宿主防御機構の解明
    科学研究費補助金
    2014年04月 - 2016年03月
    研究代表者
    B型肝炎ウイルス(HBV)に対するインターフェロン(IFN)療法の奏功率は低い。その要因の一つとしてHBVがIFN誘導性の宿主防御機構を回避する可能性が考えられる。本研究では、HBV外套蛋白質であるHBsがIFN誘導性の抗ウイルス因子の一つであるTetherinを拮抗する機能をもつことを明らかにした。HBsはTetherinと膜貫通領域で結合しその機能的二量体化を阻害した。HBs結合領域を欠損したTetherinはHBs抵抗性を示し、強い抗HBV活性を示した。HBs抵抗性Tetherinを発現させたiPS由来成熟肝細胞は顕著な抗HBV活性を示し、HBV由来の細胞傷害効果も顕著に抑制された。
    文部科学省, 若手研究(B), 横浜市立大学, 研究代表者, 競争的資金, 26860306
  • B型肝炎ウイルスの細胞侵入阻害薬の探索とその作用機序の解析
    2015年
    研究代表者
    GSKジャパン研究助成, 研究代表者
  • ヒト免疫不全ウイルス蛋白質Vpxによるウイルス感染制御機構の解明
    科学研究費助成事業
    2012年04月 - 2014年03月
    研究代表者
    宿主防御因子SAMHD1は骨髄系細胞や休止期CD4陽性T細胞においてHIV複製を抑制するが、アクセサリー蛋白質Vpxの働きによって細胞内分解される。細胞内でSAMHD1のリン酸化は抗HIV活性の制御に関与することは近年明らかになったが、一方でVpxが宿主側因子によりどのような機能的制御を受けているかは不明であった。本研究では、Vpxと相互作用する新規宿主因子を複数同定し、その機能解析を行った。その結果、Vpxは宿主細胞内の特定のリン酸化酵素によってリン酸化され、この修飾がSAMHD1の分解を促進することでウイルスの効率的な複製を可能にしていることが分かった。
    日本学術振興会, 若手研究(B), 横浜市立大学, 研究代表者, 24790447
  • ヒト免疫不全ウイルス蛋白質の翻訳後修飾とその機能解析
    2014年
    研究代表者
    横浜総合医学振興財団わかば研究助成, 研究代表者
  • ヒト免疫不全ウイルス蛋白質の翻訳後修飾機構の解明
    科学研究費助成事業
    2010年 - 2012年03月
    研究代表者
    HIV感染を防ぐための一つの手段として、ヒトの細胞はBST2などの抵抗性宿主因子BST2を保持している。しかしHIVは自身がコードするVpu蛋白質の働きによってBST2を不活化する。この活性にはVpuのリン酸化が必須であるが、その詳細な分子機構は不明である。本研究では迅速スクリーニング技術を用いて、膜輸送関連蛋白質SCYL2がVpuのリン酸化を阻害し、BST2の抗HIV活性を高めるという新たな分子モデルを明らかにした。
    日本学術振興会, 研究活動スタート支援, 横浜市立大学, 研究代表者, 22890149
  • 次世代迅速スクリーニング系を用いたヒト免疫不全ウイルス複製機構の解明
    2010年
    研究代表者
    横浜総合医学振興財団萌芽的研究助成, 研究代表者